Research Report 2016 - Chris O'Brien Lifehouse

Research Report 2016

C o m p a s s i o n i n n o V a T i o n

FOR MORE INFORMATIONChris O’Brien Lifehouse119-143 Missenden RoadCamperdown NSW 2050

Mailing AddressPO Box M5Missenden RoadCamperdown NSW 2050

Phone: 1300 852 500Fax: + 61 2 9383 1000Email: [email protected]: www.mylifehouse.org.au

Above: Professor Chris O’Brien; front cover (main) researcher; (left-right): laboratory centrifuge; Research Forum poster viewing; Clinical Trials; researcher; Dr Toni Lindsay

Chris O’Brien Lifehouse Research Report 2016 1PB

Professor Chris O’Brien AO MS MD FRCS (HON) FRACS (3 Jan 1952 - 4 Jun 2009)

Chris O’Brien was a man of leadership, vision and courage. He inspired people, both through his work as a cancer specialist and through his own three-year battle with an aggressive brain tumour.Chris transformed his personal adversity into a national opportunity, using his experience to fight so much harder for cancer patients and their families. Chris’s vision was for an integrated cancer treatment centre, where patients would no longer have to navigate their way through all the different elements of dealing with their illness alone. His vision was realised with the opening of Chris O’Brien Lifehouse to patients on 19 November 2013.

Born in 1952, Chris grew up in the western suburbs of Sydney and studied medicine at the University of Sydney, graduating in 1976. After completing his residency and surgical training at Royal Prince Alfred Hospital, Sydney, (RPAH), Chris specialised in head and neck surgery and completed clinical fellowships in England and the USA before returning to Australia in 1987 to join the staff at RPAH as a consultant head and neck surgeon.

There he contributed to the expansion of the clinical service, making it one of the largest in the country. Chris also established a basic research and international clinical fellowship program under the Sydney Head and Neck Cancer Institute, which he founded in 2002.

Chris held two postgraduate degrees from the University of Sydney — a Masters of Surgery for his basic research in microvascular surgery and a Doctorate in Medicine for his internationally recognised work on the management of metastatic cancer involving the parotid gland and neck, particularly cutaneous melanoma and non-melanoma skin cancer.

He was made an Honorary Fellow of the Royal College of Surgeons of England and in 1998 founded the Australian and New Zealand Head and Neck Society, a multidisciplinary society comprising surgeons of all

disciplines, radiation and medical oncologists and allied health professionals, and of which Chris was President in 2004.

In 2003, Professor O’Brien became Director of the Sydney Cancer Centre, based at Royal Prince Alfred Hospital. He developed a proposal to transform the Sydney Cancer Centre into a world-class comprehensive cancer centre — Lifehouse.

Chris was diagnosed with a malignant brain tumour in November 2006 and stepped down from all of his clinical and administrative positions to focus on his therapy and treatment.

Chris maintained a positive and confident outlook throughout the following few years, undergoing numerous operations and a variety of treatments including complementary therapies to ease the symptoms and side effects he was experiencing. He continued to work tirelessly on the

promotion and future construction of an integrated cancer centre (Lifehouse), which would focus on the needs and support of cancer patients, their families and carers.

The proposal to transform the Sydney Cancer Centre into a world-class comprehensive cancer centre gained the backing of the federal and state governments and was officially launched in April 2009. On Australia Day 2005, Chris was made a Member of the Order of Australia (AM) for his services to medicine and on the eve of his death (4 June 2009) he was made an Officer of the Order of Australia (AO).

Chris O’Brien Lifehouse Research Report 2016 32


Director’s ReportRebecca Davies

Board Director, Chris O’Brien Lifehouse Research Committee

On behalf of the Board of Chris O’Brien Lifehouse, it is a great pleasure to commend to you this report into research activities for 2016.

The range of research is truly reflective of key objectives we share — to be patient-centric, comprehensive and collaborative. We almost have to pinch ourselves to remember that we are such a young institution and celebrate how much has been achieved in that short time.

Something that really strikes me is how our understanding of cancer is still evolving. Much has been done, but sometimes it seems that each step forward shows us how complex the human system is and, therefore, how much more research is needed.

We are grateful for the creativity, dedication and hard work of all our researchers at Chris O’Brien Lifehouse and our partners, led by the ever-enthusiastic Prof Lisa Horvath. All our staff play their roles too, furthering our goal to bring the best treatments to our patients, supported by the best evidence.

And as you will see throughout this report, we rely on the willingness of our patients and their families to support our work — so often selflessly for the benefit of others. For this we are profoundly grateful. Finally, this important work could not happen without the philanthropic support of so many — be assured your contributions are making a real difference.

Rebecca Davies, Board Director

Opposite: Research being undertaken at

Chris O’Brien Lifehouse

Below: Proportion of studies across the

cancer tumour streams

BreastCRC

Brain

Gynae Oncology

Thoracic Oncology

ProstateNon-Prostate GUUpper GI

Sarcoma

HNSCC

Phase 1

Intergrative medicine


It is rewarding and exciting, as a healthcare consumer advocate, to attend the Research Symposiums and learn the extent of the research undertaken by Chris O’Brien Lifehouse and others over the past three years.

The drive to find new treatments that will potentially lead to better outcomes for patients is very exciting.

Lifehouse’s focus on patient-centred research and the commitment to collaboration is delivering significant information on therapies that will have a positive impact in the treatment of cancer now and well into the future.

It is gratifying and inspiring to learn of the depth and the quality of the research that Lifehouse is producing with its collaborative partners.

I am indeed honoured and inspired to have had the opportunity to be part of the Lifehouse Research collaborative.

University of SydneyNHMRC Clinical Trials

Centre, Cancer Nursing Research Unit, CeMPED,

Surgical Outcomes Research Centre

(SOuRCe)

Pharma/Biotec

Other Cancer Centres

NSW eg Concord, Westmead, St Vincents,

POW, Coffs Harbour, Newcastle

VIC eg Peter MacCallum, Royal Melbourne,

MonashSA eg SAHMRT

International eg DFCI, USC, PMCC

National Cancer Consortia

ATITG, ANZBCTG, ANZUP, ANGOG, ASSG,

POCOG

Chris O’Brien Lifehouse

Medical Oncology,Radiation Oncology,

Head and Neck Surgery,Breast Surgery,Gynaecological

Oncology

Sydney CatalystTransnational Cancer

Research Centre

RPA Institute of Academic Surgery

RPA departmentsUpper GI surgery,

neurosurgery, urology, melanoma, orthopedics, cardiothoracic surgery,

gastroenterology, pathology, haematology,

respiratory

Research InstitutesGarvan Institute / The

Kinghorn Centre, Centenary Institute, ADRI, Charles Perkins Centre, ANZAC

Institute, Melanoma Institute of Australia, Institute of

Glycomics

Bev Noble

Consumer Perspective Bev NobleConsumer Representative

Chris O’Brien Lifehouse Partnership Advisory Council


Chris O’Brien Lifehouse continues to diversify its research portfolio demonstrating the depth of research within our cancer centre and its collaborative network with over 160 publications, more than 100 national/international presentations, around 60 grants and 60 postgraduate students (Masters and PhD).

As such, this Research Report should be read as a collaborative report as Lifehouse researchers have many roles, often numerous affiliations and do their research as part of networks. The second Lifehouse Research Symposium attracted a range of speakers and poster presenters from within Lifehouse and our collaborative network across the spectrum of cancer treatment including surgery, medical oncology, radiation oncology and molecular pathology.

In 2016, the first double-blinded, placebo-controlled randomised trial of cannabis for chemotherapy-induced nausea and vomiting was opened at Lifehouse. Lifehouse clinician and researcher, A/Prof Peter Grimison, led a collaboration with Lifehouse, the NHMRC Clinical Trials Centre, Tilray and Royal Prince Alfred Hospital to develop and open the trial which is funded by NSW Health. This landmark study uses a tablet form of cannabanoids to identify if the effect is also independent of the hallucinogenic effects of recreational cannabis.

A key aspect of the Lifehouse research agenda is patient-focused research, especially that which changes clinical practice. In 2016, Lifehouse researchers contributed to changes in the practice of gynaecological oncology through contribution to NHMRC guidelines, shorter treatment protocols in men with testis cancer, changes to the staging of oral cavity squamous cell carcinoma and changes to radiation therapy practices to enhance the precision of treatment in breast and prostate cancer.

Collaboration remains the corner-stone of Lifehouse research as seen in our publications. Our Head and Neck Cancer Research Group has expanded its network across NSW, as this is an uncommon cancer and benefits significantly from combined datasets across treatment and research hubs. The Sarcoma Research Centre was also launched in 2016 at a gala dinner in the Great Hall of the University of Sydney and is taking a similar approach to centralising

Professor Lisa Horvath

Research Director’s ReportProfessor Lisa HorvathDirector of Medical Oncology and Acting Director of Research, Chris O’Brien Lifehouse

Conjoint Chair of Medical Oncology (Genitourinary Cancers) MBBS, FRACP, PhD

treatment and research for a rare cancer. Lifehouse has also partnered with St Vincent’s Hospital, Scientia Clinical Research and the Garvan Institute of Medical Research to develop the NSW Early Phase Clinical Trials Alliance (NECTA). This network is aimed at growing the early phase clinical trial portfolio in NSW, including first-in-human studies and biological window-of-opportunity studies to enhance our understanding of the potential role of new drugs in cancer therapy.


Research Committee MembersRebecca Davies Board Director, Chris O’Brien Lifehouse

Michael Boyer Clinical Director, Chris O’Brien Lifehouse

Chris Milross Director of Radiation Oncology, Chris O’Brien Lifehouse

Jonathan Carter/Sam Saidi Director of Gynaecological Oncology, Chris O’Brien Lifehouse

Jonathan Clark/Michael Elliott Research Leads Head and Neck Surgery, Chris O’Brien Lifehouse

Sanjay Warrier Research Lead Breast Surgery, Chris O’Brien Lifehouse

Christopher Young Head of Colorectal Surgery, RPAH

Paul Stalley Sarcoma tumour stream lead, RPAH/Chris O’Brien Lifehouse

Charbel Sandroussi Head of Upper GIT surgery, RPAH

Paul Bannon Head of Cardiothoracic Surgery, RPAH

Stephen Larsen Research Lead Haematology, RPAH

Graham Mann Research Director, Melanoma Institute of Australia

John Boulas Head of Urology, RPAH

James Kench Head, Cancer Diagnostics and Tissue Pathology, RPAH

Stuart Grieve Research Lead Radiology, RPAH

John Simes/Martin Stockler Director/Co-director, NHMRC CTC

Kate White Head, Cancer Nursing Research Unit

Phyllis Butow Head, CeMPED

Michael Solomon Director, RPA Institute of Academic Surgery

Julie Charlton Research Governance Manager, Chris O’Brien Lifehouse

Jacquie Harvey NUM, Clinical Research Unit, Chris O’Brien Lifehouse

Brindha Shivalingham Neuro-surgical representative

Natalka Suchowerska Head of Physics Research, Chris O’Brien Lifehouse

Toni Lindsay Head of Psycho-oncology, Chris O’Brien Lifehouse

Eileen Hannagan CEO, Chris O’Brien Lifehouse

Steven Kao Thoracic Oncology representative

Jane Young Research Director, RPA Institute of Academic Surgery

Nick Shackel RPAH Research

David Gattas Research Lead ICU, Chris O’Brien Lifehouse

Lyndal Trevena The University of Sydney Primary Health

Bev Noble Chris O’Brien Lifehouse Partnership Advisory Council

Clinical Research Unit


Researcher Profile: Dr Kate Mahon

“As a medical oncologist, I’ve seen hundreds of patients with prostate cancer. As a researcher, my aim is to find answers to the unanswered questions that we have in the clinic, to help our prostate cancer patients live better and longer, and to improve our decision-making in the clinic.

Over the past decade we’ve seen the introduction of several new drugs for prostate cancer, which have certainly helped patients in being able to live better and live longer. However, most of these drugs work in only one-half to two-thirds of patients, and we have absolutely no way of being able to tell which patients will respond to which treatments ahead of time.

This means that many patients have side effects of treatments from drugs that do not provide a benefit at all. My goal is to find some markers, preferably in the blood, which would be a very simple test, to tell me

which patients I should give which treatments to and how I should sequence these treatments to provide personalised cancer therapy.

We now have new technology which will allow us to measure DNA in blood that actually has come from the prostate cancer cells. This would give us a fantastic indication of how the prostate cancer cells themselves are changing in response to treatment and also whether they actually will respond to treatment in the first place.

We are now able to bring this technology to Australia and test these genes in our patients to see if we can marry them up with the markers we’ve already discovered to find a signature for which patients will respond to which treatments.

My research is about finding a simple blood test to guide prostate cancer treatment and to provide the best treatment for each individual patient.”

Patient Profile: Robert Newton

“My name is Robert Newton and I was diagnosed in October of 2015 with advanced stage 4 adenocarcinoma, which is lung cancer.

My doctor told me I needed to go home and put my affairs in order. When you’re told you’ve got 90 days or maybe a little more, and you may only have 30 to 60 days when you are actually able to get around to see friends and family, it certainly shakes up your whole world.

My wife did some research and found Dr Steven Kao’s name at Chris O’Brien Lifehouse. So we came down to Sydney in late October and saw Steven. He offered us the chance to stay overnight, which we appreciated as it is over five hours by train from Taree. He did quite

Dr Kate Mahon

Clinical Tumour Streams

Surgical Research

eg new devices and techniques

Collaborationsresearch institutes, biotech, pharma, universities

Supportive care

eg nursing,psychology,primary care

Transnational studieseg new

biomarkers

Clinical Trialseg new drugs


a lot of tests for us and the results were confirmed that I had advanced stage 4 adenocarcinoma. He told us that he would send the biopsies away because there might be some possible treatments.

We returned home and I was told I’d tested negative to five of the six biopsies and that it was probably unlikely that I would test positive to the sixth biopsy because it was very rare to have that genetic abnormality or genetic marker.

So at home we started to consider what our options were as it seemed that there wasn’t any treatment that could be targeted. It was a difficult time because I was considering whether to go on treatment at all or to just allow the cancer to take its natural course.

We returned a week later to Chris O’Brien Lifehouse to discuss with Dr Kao and some of the other staff what sorts of treatment, whether it was chemotherapy or radiation, were really possible. While we were in that discussion in Steven’s office an email came through which said that I’d tested positive for the ROS1 genetic marker, which is incredibly rare. This made it possible to access a treatment through this hospital.

I thought that to test positive for that ROS1 genetic marker, which is less than one in one hundred chance of having that genetic marker, was miraculous. It was also miraculous that I have this marker and there was a treatment available for me.

My understanding is that there were 50 people in Phase I of this particular trial worldwide, and in Phase II it was open to 295 participants. A certain number were allocated to a few institutions in Australia and Chris O’Brien Lifehouse was one and I’m one of the fortunate ones who was able to access it. We were able to start it on the following Friday.

I’ve had a 36 per cent reduction in the tumours being tracked. Of the two tumours in my brain, one of them has disappeared altogether, and the other has reduced by 50 per cent. It’s absolutely remarkable.”

Sadly, Robert Newtown’s trial gave him only a few months’ extra time – time that he used to gather his family for celebrations. His medical legacy is the experience he contributed to the knowledge of this trial drug.

says. “I will never be cured of cancer but the trial drug allows me to have a good life.”

Carolyn will be on the trial as long as it continues to help her. The good news is that it is now being funded by the Government.

She says: “The hardest part of my diagnosis was explaining to my granddaughters that I would lose my hair. I didn’t want to tell them about the disease at first but they are not stupid, they would have noticed that I couldn’t come to things like I used to. They knew I had always wanted to have blue hair so we were hoping together that we’d have a nice surprise when it grew back. However, it came back white and thick in the end.”

Her family and friends have been a huge support throughout the treatment. She has them on a roster, each taking turns to bring her into Chris O’Brien Lifehouse for scans and treatment. Carolyn brings lunch, and they wait with her and have a chat and catch up on the events of the world.

She also takes advantage of the complementary therapies on offer at Chris O’Brien Lifehouse, including lymphoedema massage and acupuncture for numbness in her feet and fingers after chemotherapy.

Patient Profile: Carolyn Young

When Carolyn Young (pictured) was first diagnosed with breast cancer she thought it was only an inverted nipple. The 71-year-old retiree and grandmother of three was referred to Chris O’Brien Lifehouse after a biopsy confirmed breast cancer.

Carolyn was put on a clinical trial for patients with metastatic breast cancer that expresses HER2 (a protein that stimulates the growth of breast cancer cells). This condition is conventionally treated with chemotherapy and trastuzumab, a drug which targets HER2. The trial is of an additional drug, pertuzumab which also targets HER2. The results show a better response to the whole treatment, disease-free survival and increased overall survival rates.

Carolyn has just had her 52nd treatment on the trial; she’s been on it now for three years. She has responded well to the treatment. “When I started, I had a weeping wound but this has dried up,” she

Lymphoedema massage


Medical OncologyProf Lisa Horvath MBBS FRACP PhD (Director of Medical Oncology)

A/Prof Philip Beale MBBS FRACP PhD

A/Prof Jane Beith MBBS FRACP PhD

Dr Vivek Bhadri MBBS FRACP PhD

Prof Michael Boyer AM MBBS FRACP PhD

A/Prof Peter Grimison MBBS FRACP PhD

Dr Michelle Harrison BSc (Med) MBBS FRACP

Dr Steven Kao MBBS FRACP PhD

Dr Kate Mahon MBBS FRACP PhD

A/Prof Catriona McNeil MBBS FRACP PhD

Prof John Simes BSc (Med) MBBS FRACP SM MD

Prof Martin Stockler MBBS FRACP MSc (Clin Epi)

Prof Martin Tattersall AO MBBS FRACP PhD

Prof David Thomas MBBS FRACP PhD

Research Highlights

The Medical Oncology Department has had a wide range of research achievements this year, ranging from new insights into sarcoma biology through to practice-changing studies in lung, germ cell and biliary cancers.

A/Prof Peter Grimison led the ANZUP study of accelerated BEP (bleomycin, etoposide, cisplatin) in advanced germ cell tumours. This protocol shortened the overall treatment time for this young group of patients. The recent updated results demonstrated that this approach was not only feasible as previously reported, but also the five year overall survival was 92% - consistent with standard-of-care. This data forms the basis of the currently recruiting Australian-led (Principal Investigator: A/Prof Peter Grimison) international randomised phase III trial comparing accelerated versus standard BEP chemotherapy (Australian New Zealand Clinical Trials Registry: ACTRN12613000496718).

EGFR-mutant non-small cell lung cancer represents 20% of Australian lung cancer patients, mainly those that are non-smokers and more frequently women. Prof Michael Boyer was a key member of the consortium which assessed the 1st generation

(gefinitib) vs 2nd generation (afatinib) EGFR-inhibitors in first line treatment for this type of lung cancer. This randomised Phase 2 study (LUX-Lung 7) demonstrated that the newer drug, afatinib, improved clinical outcomes with a manageable side effect profile. Additionally, a pooled-analysis of two randomised trials of erlotinib vs the newer dacomitinib, both EGFR-inhibitors, demonstrated they have comparable effects in the patients with EGFR-mutant lung cancers. Furthermore, the subgroup with exon 19 deletions had potentially better outcomes with dacomitinib. These studies continue the process of defining the optimal precision medicine strategies in ERGF-mutant lung cancer in an era of new therapeutics aimed at overcoming previous drug-resistance.

In conjunction with the Asbestos-Diseases Research Institute, Dr Steven Kao has furthered his work into circulating biomarkers for diagnosis and prognosis in metastatic malignant mesothelioma. Dr Kao led a study that identified high levels of circulating SPARC (secreted protein acidic and rich in cysteine) as a poor prognostic factor in malignant mesothelioma.

The group has also published a study this year assessing circulating Activin as a marker of the cancer morphology in mesothelioma with high levels associated with sarcomatoid and biphasic mesothelioma and low levels with epithelioid mesothelioma. This work is part of the ongoing process of identifying tissue and blood-based biomarkers to guide therapy.

The launch of the CannabisCINV, a placebo-controlled trial evaluating an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting in cancer patients, led by A/Prof Grimison in collaboration with NSW Health, Tilray and the NHMRC Clinical Trials Centre, University of Sydney. This high profile study will rigorously define the role of cannabis in chemotherapy-induced nausea and vomiting.

The clinical trials portfolio has expanded with over 50 clinical trials across all solid tumour types including rare cancers such as sarcoma and head and neck squamous cell carcinomas. The trial activity is now ~30% Phase 1 with seven first-in-human studies recruited during 2016.

Publications 76

Presentations (national/international) 58

Students 6

Grants 31


Radiation OncologyA/Prof Christopher Milross MBBS MD FRANZCR FRACMA FAICD (Director of Radiation Oncology)

Dr Susan Carroll MBBS FRANZCR

A/Prof Kerwyn Foo BSc MBBS FRANZCR

Dr Leily Gholemrezai MBBS FRANZCR

A/Prof Angela Hong MBBS MMed PhD FRANZCR

Dr Nitya Patanjali MBBS FRANZCR

Dr Leily Rezaei MBBS FRANZCR

Dr Mo Mo Tin MBBS FRANZCR

Dr Joanne Toohey MBBS FRANZCR FRACP MRCP

Dr Regina Tse MBBS MClinEpi FRANZCR

Publications 24


Students 12

Grants 3

Research Highlights

Radiation treatment is an essential and cost-effective cancer treatment. However, it is under-utilised in Australia in part due to patients’ perceptions. In a study of over1,000 patients, Sundaresan et al identified a series of factors which were moderate-to-strong influencers of the decision whether to have radiotherapy: concern about acute and chronic side effects; management of side effects; fear and anxiety about radiotherapy; lack of local availability of radiotherapy; and lack of radiotherapy information resources.

This study will influence clinical practice by identifying a need for increased information, support services and understanding of radiotherapy to increase patient utility of this treatment.

In the area of radiation planning, there have been significant advances in the optimisation of radiation treatment. Dr Susan Carroll has led a group looking at how to best treat women with breast cancer needing radiotherapy after mastectomy and breast tissue expanders for breast reconstruction.

This study identified that the radiation dose is attenuated in the ‘shadow’ of the tissue expander port. However, this is likely to be insignificant clinically.

Similarly, Dr Patanjali assessed the role of a fiducial marker image-guided radiotherapy in prostate cancer, in which the fiducial marker is used to correct errors of setup and motion to improve target accuracy. The study demonstrated that prostate cancer patients achieved good fiver year cancer control with low rates of toxicity.

Dr May Whittaker and Radiation Oncology colleague


Breast SurgeryA/Prof Hugh Carmalt MBBS FRACS FRCS (Director of Breast Cancer Surgery)

Dr Belinda Chan MBBS FRACS MS

Dr Cindy Mak MBBS (Hons) FRACS

A/Prof Sanjay Warrier BSc (Med) MBBS FRACS MS

Research Highlights

During 2016, the Breast Surgery Department continued to foster the development of research through strong relationships in a number of key areas such as translational and laboratory based research, surgical outcomes and innovation.

In collaboration with Prof Elgene Lim from the Garvan Institute of Medical Research, a collaborative grant was awarded to assess the biological role of progestin in a neoadjuvant study. This will allow the study of breast cancer tissue pre- and post- progestin treatment to identify markers of biological activity. This project paves the way for a neoadjuvant trials program which will improve the understanding of drug resistance in breast cancer.

The group was involved in a significant study evaluating the surgical, aesthetic and quality of life outcomes in 47 women undergoing immediate implant-based breast reconstruction followed by post-mastectomy radiotherapy. The study demonstrated acceptable cosmetic results, high patient satisfaction and low complication rates. The results provide evidence that women are willing to accept the potential risks of immediate implant-based breast reconstruction in exchange for its benefits including enhanced body image during chemotherapy and post-mastectomy radiotherapy. This is a serious problem for women with breast cancer and supports the importance of access to breast reconstruction even in women with high-risk disease.

In 2016, a prospective database was established to capture modern surgical and chemotherapy technologies as the base for future study and to conduct decision impact clinical utility studies such as the FAXITRON study (intraoperative X-ray). In this study, innovative technology such as a lead site was reviewed, including ICG Angiography (SPY) for flap perfusion and novel assessment of sentinel nodes, engagement of robotics in axillary surgery and 3D printing in breast surgery.

The Breast Surgery Department has also developed a breast surgery Master’s program at University of Sydney, coordinated by A/Prof Sanjay Warrier. This will encourage more research training in breast surgery and help to build the next generation of clinical researchers in this field.

Publications 5


Students 14

Grants 2

Dr Cindy Mak performing breast cancer surgery


Research Highlights

The Gynaecological Oncology Group has achieved significant research outcomes in the past year.

A study was completed of 550 consecutive patients undergoing Fast Track Surgery (FTS) after laparotomy to identify predictors of early discharge,optimising a patient’s recovery after surgery. The mean length of stay (LOS) was 3.4 days with 194 (35%) patients discharged on day two. Six (1%) patients had confirmed venous thromboembolism (VTE), three of whom were diagnosed on preoperative imaging. Factors associated with a discharge on or after day three include age, pathology, ECOG performance status, incision type, operating time, blood transfusion and COX2 inhibitors. Factors associated with hospital readmission include longer operating time, performance of lymph node sampling/dissection, longer LOS, development of wound infection, febrile morbidity, return to the operating room, unplanned ICU admission and presence of other complications. Patients managed by a FTS protocol can expect enhanced outcomes when compared to historical controls.

Another study was undertaken and related research article published exploring the effect of the prescription of extended thromboprophylaxis after implementation of an individualised venous thromboembolism (VTE) risk

Publications 23


Students 2

Grants 0

Gynaecological Oncology

Prof Jonathan Carter MBBS Dip RACOG FACS FRANZCOG CGO MS MD (Director of Gynaecological Oncology)

A/Prof Selvan Pather MBChB FCOG FRANZCOG CGO

A/Prof Sam Saidi MBChB MRCOG FRANZCOG PhD

A/Prof Trevor Tejada-Berges MD MSc FRCPSC FACOG FRANZCOG

assessment tool in gynaecological oncology surgical patients. The study comprised of a retrospective cohort of 766 women who underwent open and laparoscopic gynaecology surgery for benign and malignant conditions at a Chris O’Brien Lifehouse. The women were divided into the Pre-Caprini group who had surgery in the 12 months prior to implementation of the Caprini Score process and the Post-Caprini group. Implementation of the Caprini Score resulted in a significant increase in the prescription of extended thromboprophylaxis without an increased risk of postoperative haemorrhagic complications. However, there was no decrease in rates of venous thromboembolism.

A study was completed and presented through a partnership between Lifehouse and the QIMR Berghofer Medical Research Institute, Queensland, using a national database to identify factors affecting the progression-free survival and overall survival in Stage 2 corpus cancer and to assess the impact of the new FIGO classification in terms of progression-free survival and overall survival, compared to the old system.

The main findings were that the management of stage II endometrial cancer was variable in terms of type of surgery and adjuvant treatment administered. However, most of them would have had radiation as part of their therapy. Factors affecting overall

survival were age, cytology and use of chemotherapy. Factors affecting progression-free survival were only lymphovascular space invasion.

No difference was demonstrated in the progression-free survival and overall survival between those with cervical glandular involvement only versus cervical stroma invasion. Based on the available evidence, surgery followed by adjuvant treatment for Stage 2 endometrial cancers is the recommendation, especially for those with adverse cytology/lymphovascular space invasion. Examination prior to surgery is important to assess parametrium. If no parametrial involvement is found, a simple hysterectomy should suffice. Closer follow up for patients with lymphovascular space invasion in the initial 2-3 years is advised as the length of time to recurrence may be significantly shorter.

Prof Jonathan Carter


Head and Neck SurgeryA/Prof Carsten Palme MBBS FRACS (Director Head and Neck Surgery)

Dr Bruce Ashford MBBS FRACS BDSc (Hons)

A/Prof Sydney Ch’ng MBBS FRACS PhD

Prof Jonathan Clark MBBS (Hons 1) BSc (Med) MBiostat FRACS

Dr Anthony Clifford MBBS FRACS

A/Prof Ardalan Ebrahimi MBBS FRACS MPH

A/Prof Michael Elliott MBBS MPhil FRACS

Dr Lydia Lim BDS (Hons) FRACDS MDSc FRACDS (OMS)

Dr Hubert Low MBBS BSc (Med) (Hons) FRACS

Dr John McGuinness BDS(Hons) FDS RCS MBChB FRCS(ORL-HNS) FRACS

A/Prof Navin Niles MBBS FRACS

Dr Daniel Novakovic MBBS FRACS MPH

A/Prof Mark Schrifter BDS MDSc M SND RCSEd M Oral M RCSEd FFD RCSI FRACDS

Dr Kerwin Shannon MBBS FRACS

Dr Jasvir Singh BDS MBBS D ClinDen (OMS) FRACDS (OMS)

Dr Sue-ChingYeoh BDS (Hons) MDSc MPhil FRACDS FRACDS (Oral Med)

Research Highlights

Using the Sydney Head and Neck Cancer Institute database, which currently includes 14,000 cases, research in the Lifehouse Head and Neck Unit (HNU) has traditionally focused on two areas: 1. Disease outcomes following surgery and radiotherapy, and 2. Patient-reported outcomes on quality of life.

More recently, the database has facilitated a strong translational research program exploring the pathological and molecular markers of metastases and prognosis in head and neck cancer. This has been possible through collaborations with the Department of Anatomical Pathology at the Royal Prince Alfred Hospital, the Illawarra Medical Health and Research Institute at the University of Wollongong and the Garvan Institute of Medical Research.

The HNU has successfully developed and maintained a biobank of head and neck tumours, including blood, fresh tissues (normal and malignant) and concurrent formalin fixed paraffin embedded tissues and cognate clinicopathologic data.

In 2016, the HNU ran new clinical trials to investigate immune checkpoint inhibitors in unresectable and metastatic head and neck cancers. In addition, the unit has a growing interest in patient education, through collaborations with the University of Sydney, as well as bionic facial reanimation through the University of New South Wales.

Novel anti-PD1/PD-L1 antibodies are showing promise as therapeutics in oral cavity squamous cell carcinoma (OSCC) patients. However, data regarding PD-L1 expression in OSCC is limited. Immunohistochemistry with PD-L1, CD4 and CD8 was performed on 217 patients with OSCC. Forty (18.3%) cases showed PD-L1 expression. Expression was significantly more frequent in females (p=0.013), tongue/buccal mucosal SCCs (p=0.05), and in tumours with a high lymphocytic infiltrate (p>0.001). PD-L1 expression was not associated with disease-free (p=0.82) or overall survival (p=0.93). Frequent PD-L1 expression in OSCCs in females and in tumours with high lymphocytic infiltrate may assist in the selection of patients who may respond to anti-PD1/PD-L1 therapies.

The HNU has continued to pursue the identification of prognostic biomarkers in cutaneous squamous cell carcinoma through a multimodality approach including genomic profiling, in vitro/in vivo investigations and immune markers. In a first for this disease, the Unit has identified circulating tumour cells in patients’ regional metastatic cSCC. This represents a breakthrough in the field with the potential to be a marker of early recurrence and a mechanism to understand more about the biology of this cancer.

Another key biomarker in OSCC is p16 with its association with human papillomavirus (HPV) and prognosis in oral cavity squamous cell carcinoma (OSCC). The group assessed p16 immunohistochemistry and HPV in situ hybridisation on 215 patients with OSCC. Amongst patients receiving adjuvant radiotherapy, patients with p16 expression had a significantly longer disease-free period and overall survival. The p16 expression was seen in early stage OSCCs and was associated with better survival following surgery and radiotherapy. While not an independent predictor of survival, p16 may mediate its effects by contributing to reduced proliferative capacity, leading to smaller tumour size and lower invasive potential.

Important studies from the International Consortium for Outcome Research (ICOR) in Head and Neck Cancer were published on staging of OSCC with Associate Prof Ebrahimi as the lead author and Prof Clark as a senior author. This led to changes in the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging manual for OSCC published in 2016.

Publications 54


Students 29

Grants 1


Research Highlights

The Integrative Medicine Group has been through a detailed strategic planning process to consolidate resources and identify opportunities for research in this area. A key area of focus in the plan is the establishment of a supportive care database.

A study was undertaken looking at supportive care for immunotherapy patients. The primary objective was to assess the feasibility of providing a multimodal supportive care program for melanoma patients being treated with pembrolizumab. A secondary objective was to explore the lived experience of being on pembrolizumab treatment for advanced melanoma. As part of the study, a medical oncologist or a cancer nurse specialist purposively recruited twenty-eight participants with metastatic melanoma undergoing 3-weekly pembrolizumab therapy. Patients could elect to participate in the intervention arm of the study, or in the ‘control’ arm. Thirteen participants were recruited to the treatment cohort, which included baseline medical oncology assessment and clinical assessments with a supportive care physician, exercise physiologist and dietitian. Participants in each cohort completed patient-reported outcomes questionnaires at baseline, 3-weeks, 6-weeks, 9-weeks, and 3-weeks post-intervention. The questionnaires amalgamated the validated HADS, ESAS, FACT-G, and PG-SGA tools

for patient-reported outcomes. During open-ended discussion with the supportive care physician, the treatment cohort participants were referred for supportive care therapies, including acupuncture, massage, reflexology, qi gong, mindfulness meditation, and psycho-oncology. A subsequent supportive care evaluation was completed at 9 weeks. The 16 participants in the control cohort completed 3-weekly questionnaires and an interview at 9 weeks only.

Work has continued on addressing the significant gap that exists across NSW in the delivery of coordinated pre-rehabilitation (pre-surgery) or rehabilitation (post-surgery) for lung cancer patients. A rehabilitation program post-surgery is not consistently applied to patients undergoing surgery

at major tertiary centres or for those returning to rural locations. While all sites have resources and provide quality services, there is currently no consistent, ongoing follow-up of patients post-surgery to monitor physical rehabilitation. Equally, there is no formalised networking across sites currently for post-surgical care or professional development amongst the healthcare professionals providing these services. Existing pulmonary rehabilitation programs tend to focus on chronic obstructive airways disease and other chronic conditions, rather than lung cancer and surgical follow up. Pulmonary rehabilitation is a minimally invasive multidisciplinary therapeutic intervention that has demonstrated positive outcomes for lung cancer patients in various settings. Mounting evidence supports the importance of preparing newly diagnosed cancer patients and optimising their health before starting intense treatments such as surgery or chemotherapy. There are few, if any, examples of harnessing eHealth technologies in a consistent way to improve preparation for surgery or rehabilitation post-surgery. The study being undertaken extends existing Sydney Catalyst research projects in lung cancer care and aims to evaluate the feasibility of an integrated model of care for pre-rehabilitation/rehabilitation of patients undergoing surgery for non-small-cell lung cancer, commencing with a Phase I study of the physical exercise component, utilising blended delivery including telehealth and face-to-face methods.

Publications 0


Students 1

Grants 1

Integrative MedicineDr Judith Lacey MBBS FRACGO FAChPM (FRACP) (Director of Integrative Medicine)

Dr Toni Lindsay PhD (Clin & Health Psych) (Clinical Psychologist)

Mr Michael Marthick BSc (Ex Sci), Grad Dip Sc (Ex Rehab), MPH (Exercise Physiologist)

Dr Suzanne Grant BAppSc (TCM), MPS, PhD (Chinese Medicine) (Acupuncturist)

Michael Marthick, Exercise Physiologist, with patients in The LivingRoom gym


Lifehouse AffiliatesNHMRC Clinical Trials Centre

The NHMRC Clinical Trials Centre (CTC) at the University of Sydney conducts large-scale, multi-centre, investigator-initiated, academic clinical trials with national and international trial groups, and contributes expertise to trials run by others. The CTC’s Oncology Group based at Lifehouse works in partnership with Australia’s leading cancer collaborative investigator groups. The CTC is the coordinating centre for the:

• Australasian Gastro-Intestinal Trials Group (AGITG)

• Australasian Lung Cancer Trials Group (ALTG)

• Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

• Australia New Zealand Gynaecological Oncology Group (ANZGOG)

• Cooperative Trials Group for Neuro-Oncology (COGNO).

The CTC is also the statistical centre for the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).

The NHMRC CTC and Lifehouse work together on a number of studies, including the NITRO/BR.26 studies in lung cancer, ENZARAD/ENZAMET in prostate cancer, PCR-MIB in bladder cancer, VERTU in brain cancer and ASCOLT in colorectal cancer.

CeMPED and PoCoG

The Centre for Medical Psychology and Evidence-based Medicine (CeMPED) was launched in 2008 as a University of Sydney Research Centre, combining two previous research groups which had been functioning informally for many years. It is cross-disciplinary and multi-faculty, with members in the School of Psychology, School of Public Health and the Department of Medicine. All staff and students, except those associated

with the School of Public Health, are housed on the 6th floor of Lifehouse, and focus exclusively on research in the Oncology population, across the trajectory of the disease from living with high risk, to diagnosis and survivorship, to end of life care. CeMPED’s research interests focus on behaviours and interventions to:

• Promote good health and prevent disease

• Enhance psychosocial adjustment of patients and carers

• Increase use of evidence in health care decision making

• Support patients to be more involved in their own health care

Focus on vulnerable patients, such as immigrants, with low health literacy, who are living in rural and remote areas, and at the end of life.

CeMPED currently has over 50 staff and students. Since 2010, staff have won more than $10,000,000 in grants and published over 300 papers in peer reviewed journals.

The Psycho-Oncology Co-operative Research Group (PoCoG) was launched in 2005, and is one of the 14 national cancer clinical trial groups under the umbrella of Clinical Oncology Society of Australia (COSA), and funded by Cancer Australia. It has over 1,500 members across Australia. PoCoG’s mission is to support internationally significant, collaborative, psycho-oncology research and to provide resources and mentorship to psycho-oncology researchers. PoCoG works closely and collaborates with the other trial groups, and is currently supporting 44 studies.

Current in-house research within CeMPED and PoCoG includes:

• ConquerFear: A Cancer Australia-funded multi-centre randomised controlled trial of a psychologist-delivered intervention to assist survivors to better manage fear of cancer recurrence (PI: Professor Phyllis Butow, PoCoG). This is now completed. The results are being presented as an oral (with associated media release) at ASCO in June, by

Prof Jane Beith from Lifehouse, who was a CI on the grant. The main outcome paper is under review by JCO, which has invited revisions (submitted). The study found that the intervention (ConquerFear) reduced fear of cancer recurrence and general anxiety and improved quality of life significantly more than the active control (relaxation therapy), with results maintained to 6-month follow-up.

• ADAPT: A Cancer Institute NSW translational program grant evaluating implementation strategies for a clinical pathway to manage anxiety and depression in cancer patients (PI, Prof Phyllis Butow, PoCoG). The preliminary phase of this study, in which all required resources to enact the clinical pathway were developed and evaluated, has been completed. A pilot at one hospital site is near to completion. The cluster randomised controlled trial of implementation strategies is underway, with more than the required 12 sites recruited and 5 sites currently being activated. Lifehouse is participating in the evaluation of health professional education regarding the pathway, and will also be a site in the main trial.

• RAVES: A Prostate Cancer Foundation-funded randomised controlled trial of a decision aid to support men with high risk prostate cancer in deciding whether to join the TROG RAVES trial of early vs late radiotherapy (PI Dr Puma Sundaresan, radiation oncologist), is completed. The main paper has been submitted for publication and several other papers are underway. The study found that the decision aid significantly reduced decisional conflict and improved knowledge compared to the control group. It also increased the number of patients who decided to enrol on the trial.

• Advanced care planning: An NHMRC-funded randomised controlled trial of advanced care planning delivered by trained nurses of patients with less than one year to live has been completed. This study was led by Prof Martin Tattersall, medical oncologist at Lifehouse.


Lifehouse was a site in the study. The study results are currently being written up for submission.

• e-TC: An ANZUP-funded study involving further development and piloting of an internet-based therapy for testicular cancer survivors to reduce anxiety and depression is underway. The study is led by Dr Ben Smith (CeMPED); A/Prof Peter Grimison (medical oncologist from Lifehouse) is a CI on the study.

• Challenge: An NHMRC-funded randomised controlled trial of exercise for colorectal cancer survivors (PIs Prof Janette Vardy – medical oncologist and Dr Haryana Dhillon, CeMPED) is nearing completion, with additional funding from Sydney

project developing evidence to support a decision aid for women with DCIS (PIs Prof Madeleine King and Dr Claudia Rutherford, PoCoG) has been completed. Several systematic reviews to inform the decision aid have been completed and submitted for publication.

• PiGEON (PI Prof Phyllis Butow, CeMPED, with post-doc Dr Megan Best) – Two psychosocial substudies of the Genome Cancer Medicine Programme are being led by Prof David Thomas at Kinghorn Cancer Centre. These studies will determine knowledge, attitudes, views and preferences, and psychological adjustment, of two cohorts from: a) the Cancer Risk study, recruiting 1,000 patients, primarily under the age of 40, with cancers of likely genetic origin, who will receive whole genome testing and b) the MOST study, recruiting 1,000 patients with advanced cancer being offered mutation panel testing. The PiGEON study will monitor outcomes before, while waiting and after receipt of test results, and place findings in an ethical context. Lifehouse will be participating as a study site.

The Cancer Nursing Research Unit (CNRU)

CNRU has continued to focus their work on expanding the contribution of cancer nurses in the delivery of quality cancer services. This includes the extended role of nurses in both clinical and community sectors.

The CNRU conducts its research activities under four themes: (1) supportive care, (2) psychosocial and quality of life, (3) models of health care delivery and (4) improving research capacity and skills for cancer and palliative care nurses.

The ongoing research and activities include:

• Evaluating a shared care pathway intervention to reduce chemotherapy outpatients’ unplanned presentations to hospital (a partnership with Lifehouse and Concord Repatriation General Hospital)

• An Education Support Program for carers of patients receiving Bone Marrow Transplant

Catalyst to perform long-term follow-up.

• Re-Kindle: An ARC-funded randomised controlled trial of an online intervention for cancer survivors in managing sexual dysfunction after cancer (PI Dr Haryana Dhillon, CeMPED) is nearing completion.

• TRIO – An ARC-funded pilot of online training for health professionals in ethical involvement of family members in consultations and decision-making (PI A/Prof Ilona Juraskova, CeMPED) is underway. Recruitment for the pilot has not yet commenced.

• Ductal Carcinoma in situ (DCIS) decision aid is a Medibank-funded

Number of patients on clinical trials across the cancer tumour streams

Phase I-III studies across the cancer tumour streams


• Evaluating haematology patients’ and health professionals’ attitudes to complementary and alternative medicine

• Assessing adolescent and young adult cancer patients’ transition to palliative care and the effect on health care professionals

• Interventions to improve supportive care.

The CNRU is a member group of Sydney Catalyst and supports clinical nurses in their research projects as well as hosting a talented group of postgraduate degree students.

Sydney Catalyst

Chris O’Brien Lifehouse is one of the original member groups of Sydney Catalyst and the relationship between the two organisations has gone from strength to strength over the last few years. The Sydney Catalyst central office is housed within the Lifehouse building. This has provided an important opportunity for the groups to work closely together across a range of translational research projects and activities, challenging institutional and work culture boundaries. Co-location also provides Sydney Catalyst staff with a unique opportunity to experience the inner workings of Lifehouse, enriching their understanding of clinical practice and breaking down some of the walls between researchers and clinicians.

The involvement of Lifehouse’s Chief Clinical Officer, Professor Michael Boyer, with the Sydney Catalyst Governing Council and Executive team further supports the relationship, as does the involvement of Lifehouse’s Director of Research, Professor Lisa Horvath, on the Sydney Catalyst Scientific Advisory Committee.

EnRICH and LC-PLAT are two important examples of specific translational research collaborations between Lifehouse and Sydney Catalyst.

LC-PLAT

Led by Lifehouse Medical Oncologist Dr Steven Kao, the LC-PLAT project

(Lung Cancer Cohort - a Platform to Study Serial Biospecimens and Matched Clinical Data) commenced in mid-2015. Its aim was to establish the infrastructure needed to identify and recruit lung cancer patients from Lifehouse for the collection of detailed data and serial biospecimens (tissue and blood) and to enable a range of translational studies. These include:

• Rapid molecular profiling by next-generation sequencing

• Studies of potential prognostic biomarkers and predictive biomarkers of response and resistance to treatments using wide ranging experimental platforms -

• Genomic and Immunological studies

• Dynamic animal models from matched patient tumour tissue i.e. patient-derived xenografts

• Circulating biomarker studies including circulating tumour DNA in blood plasma.

Since its commencement, the study has successfully recruited around 20 patients with data and samples being shared amongst project collaborators to enable specific translational research questions to be addressed. Importantly, the project has also informed and provided a framework for the complex scientific, operational and governance arrangements required for similar programs of work. This has included Sydney Catalyst’s newest flagship program EnRICH.

EnRICH

The Embedding Research in Cancer Healthcare (EnRICH) is a new major flagship translational cancer research program for Sydney Catalyst of which Lifehouse is a significant partner.

EnRICH will assemble a patient cohort to:

• Describe the natural history of and patterns of care for lung cancer

• Identify current gaps in evidence and practice for clinical quality improvement

• Create a platform for researchers across the T1-T3 translational

research spectrum to develop and initiate clinical research and intervention studies to address gaps

Initially lung cancer will be an exemplar. Professor Michael Boyer is a clinical lead for EnRICH and it is expected that a significant proportion of patients to be involved in EnRICH will be recruited from and/or treated at Lifehouse. Some of the key research questions to be addressed by EnRICH initially include;

• What are the molecular and disease and patient characteristics of patients with lung cancer?

• What is the natural history of patients with lung cancer in terms of recurrence-free survival, overall survival and patient reported outcomes? What are main prognostic factors for these outcomes related to molecular, disease and patient characteristics?

• What are current patterns of care for patients with lung cancer? How and why do patterns of care vary?

Significant new research opportunities will also be made possible by EnRICH, enabling Sydney Catalyst members (600+ at the end of 2016) and others locally and internationally to use the resource to improve outcomes for people affected by cancer.

Royal Prince Alfred Hospital – Institute of Academic Surgery (IAS)

The RPA Institute of Academic Surgery (IAS), which was established within the Sydney Local Health District (SLHD) in 2014, has the primary aim of reinvigorating the discipline of academic surgery on the broader RPA and University of Sydney campus. Through the implementation of new and innovative models that support the development of academic careers and the uptake of surgical research and education, the Institute has been working in close partnership with Lifehouse across both surgical and medical specialties. In 2016, this has included significant collaboration and planning for the introduction of the second state-wide centre for peritonectomy services at RPA


in 2016, with Lifehouse staff from Gynaecological Oncology and Medical Oncology working together with the IAS, Colorectal and many other clinical teams to prepare for the new clinical service and research program.

The IAS also has well-established Research and Education Leads within each surgical specialty including Breast Surgery, Gynaecological Oncology and Head and Neck Surgery at Lifehouse, and meets with these surgical staff regularly to discuss current research and education projects, academic planning, any challenges being encountered and upcoming opportunities for collaborations. Surgical staff at Lifehouse are involved in the provision of teaching and mentoring within the IAS Surgical Science Mentorship Program aimed at providing guidance and support to junior medical staff preparing to sit the primary surgical examination. In addition, the IAS is working together with Lifehouse surgical staff to supervise a number of research projects being undertaken by MD students at the University of Sydney.

Medical Oncology Publications 1. AIX, S. P., PARK, K., TAN, E. H., O’BYRNE, K., ZHANG, L., BOYER, M., MOK, T., HIRSH, V., CHIH-HSIN YANG, J., MARTEN, A. & PAZ-ARES, L. 2016. P1.34: First-line afatinib vs gefitinib for patients with EGFR mutation-positive non-small-cell lung cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC. Journal of Thoracic Oncology, 11, S203-S204.

2. AL-EISAWI, Z., BEALE, P., CHAN, C., YU, J. Q., PROSCHOGO, N., MOLLOY, M. & HUQ, F. 2016. Changes in the in vitro activity of platinum drugs when administered in two aliquots. BMC Cancer, 16, 688.

3. ARZUMAN, L., BEALE, P., YU, J. Q. & HUQ, F. 2016. Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and

Curcumin in Human Ovarian Cancer Cell Lines. Anticancer Res, 36, 2809-18.

4. BALLINGER, M. L., GOODE, D. L., RAY-COQUARD, I., JAMES, P. A., MITCHELL, G., NIEDERMAYR, E., PURI, A., SCHIFFMAN, J. D., DITE, G. S., CIPPONI, A., MAKI, R. G., BROHL, A. S., MYKLEBOST, O., STRATFORD, E. W., LORENZ, S., AHN, S. M., AHN, J. H., KIM, J. E., SHANLEY, S., BESHAY, V., RANDALL, R. L., JUDSON, I., SEDDON, B., CAMPBELL, I. G., YOUNG, M. A., SARIN, R., BLAY, J. Y., O’DONOGHUE, S. I., THOMAS, D. M. & INTERNATIONAL SARCOMA KINDRED, S. 2016a. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol, 17, 1261-71.

5. BALLINGER, M. L., THOMAS, D. M. & INTERNATIONAL SARCOMA KINDRED, S. 2016b. Sarcoma and germ-line DICER1 mutations - Authors’ reply. Lancet Oncol, 17, e471.

6. BECKERS, R. K., SELINGER, C. I., VILAIN, R., MADORE, J., WILMOTT, J. S., HARVEY, K., HOLLIDAY, A., COOPER, C. L., ROBBINS, E., GILLETT, D., KENNEDY, C. W., GLUCH, L., CARMALT, H., MAK, C., WARRIER, S., GEE, H. E., CHAN, C., MCLEAN, A., WALKER, E., MCNEIL, C. M., BEITH, J. M., SWARBRICK, A., SCOLYER, R. A. & O’TOOLE, S. A. 2016. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69, 25-34. *

7. BEITH, J., BURSLEM, K., BELL, R., WOODWARD, N., MCCARTHY, N., DE BOER, R., LOI, S. & REDFERN, A. 2016. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. Asia-Pacific Journal of Clinical Oncology, 12 Suppl 1, 3-18.

8. BLINMAN, P., MILESHKIN, L., KHAW, P., GOSS, G., JOHNSON, C., CAPP, A., BROOKS, S., WAIN, G., KOLODZIEJ, I., VEILLARD, A. S., O’CONNELL, R., CREUTZBERG, C. L. & STOCKLER, M. R. 2016. Patients’ and clinicians’ preferences for adjuvant

chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115, 1179-1185.

9. BOYER, M. J., GU, L., WANG, X., KELSEY, C. R., YOO, D. S., ONAITIS, M. W., DUNPHY, F. R., CRAWFORD, J., READY, N. E. & SALAMA, J. K. 2016. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer, 98, 76-8.

10. BREMNES, R. M., BUSUND, L. T., KILVAER, T. L., ANDERSEN, S., RICHARDSEN, E., PAULSEN, E. E., HALD, S., KHANEHKENARI, M. R., COOPER, W. A., KAO, S. C. & DONNEM, T. 2016. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. Journal of Thoracic Oncology, 11, 789-800.

11. BROWN, C. A., SUNEJA, G., TAPELA, N., MAPES, A., PUSOENTSI, M., MMALANE, M., HODGEMAN, R., BOYER, M., MUSIMAR, Z., RAMOGOLA-MASIRE, D., GROVER, S., NSINGO-BVOCHORA, M., KAYEMBE, M., EFSTATHIOU, J., LOCKMAN, S. & DRYDEN-PETERSON, S. 2016. Predictors of timely access of oncology services and advanced-stage cancer in an HIV-endemic setting. The Oncologist, 21, 731-8.

12. BRUCE, H. M., STRICKER, P. D., GUPTA, R., SAVDIE, R. R., HAYNES, A. M., MAHON, K. L., LIN, H. M., KENCH, J. G. & HORVATH, L. G. 2016. Loss of AZGP1 as a superior predictor of relapse in margin-positive localized prostate cancer. The Prostate, 76, 1491-1500.

13. BURGESS, A., CHIA, K. M., HAUPT, S., THOMAS, D., HAUPT, Y. & LIM, E. 2016. Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol, 6, 7.

14. CHAMBERS, S. K., FOLEY, E., CLUTTON, S., MCDOWALL, R., OCCHIPINTI, S., BERRY, M., STOCKLER, M. R., LEPORE, S. J., FRYDENBERG, M., GARDINER, R. A., DAVIS, I. D. & SMITH, D. P. 2016. The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Quality of Life Research, 25, 3027-3035.


15. CHAMBERS, S. K., OCCHIPINTI, S., FOLEY, E., CLUTTON, S., LEGG, M., BERRY, M., STOCKLER, M. R., FRYDENBERG, M., GARDINER, R. A., LEPORE, S. J., DAVIS, I. D. & SMITH, D. P. 2016. Mindfulness-based cognitive therapy in advanced prostate cancer: a randomized controlled trial. Journal of Clinical Oncology, 35, 291-297.

16. DONG, S. T., BUTOW, P. N., AGAR, M., LOVELL, M. R., BOYLE, F., STOCKLER, M., FORSTER, B. C. & TONG, A. 2016a. Clinicians’ perspectives on managing symptom clusters in advanced cancer: a semistructured interview study. Journal of Pain and Symptom Management, 51, 706-717 e5.

17. DONG, S. T., BUTOW, P. N., TONG, A., AGAR, M., BOYLE, F., FORSTER, B. C., STOCKLER, M. & LOVELL, M. R. 2016b. Patients’ experiences and perspectives of multiple concurrent symptoms in advanced cancer: a semi-structured interview study. Supportive Care in Cancer 24, 1373-86.

18. DRIML, J., PULFORD, E., MOFFAT, D., KARAPETIS, C., KAO, S., GRIGGS, K., HENDERSON, D. W. & KLEBE, S. 2016. Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas. Int J Mol Sci, 17.

19. DU BOIS, A., KRISTENSEN, G., RAY-COQUARD, I., REUSS, A., PIGNATA, S., COLOMBO, N., DENISON, U., VERGOTE, I., DEL CAMPO, J. M., OTTEVANGER, P., HEUBNER, M., MINARIK, T., SEVIN, E., DE GREGORIO, N., BIDZINSKI, M., PFISTERER, J., MALANDER, S., HILPERT, F., MIRZA, M. R., SCAMBIA, G., MEIER, W., NICOLETTO, M. O., BJORGE, L., LORTHOLARY, A., SAILER, M. O., MERGER, M., HARTER, P. & CONSORTIUM, A. G. O. S. G. L. G. C. I. E. N. O. G. O. T. G. I. 2016. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 17, 78-89. (Beale P as part of a consortium)

20 DUCHESNE, G. M., WOO, H. H., BASSETT, J. K., BOWE, S. J., D’ESTE, C.,

FRYDENBERG, M., KING, M., LEDWICH, L., LOBLAW, A., MALONE, S., MILLAR, J., MILNE, R., SMITH, R. G., SPRY, N., STOCKLER, M., SYME, R. A., TAI, K. H. & TURNER, S. 2016. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncology, 17, 727-37.

21. DYLKE, E. S., SCHEMBRI, G. P., BAILEY, D. L., BAILEY, E., WARD, L. C., REFSHAUGE, K., BEITH, J., BLACK, D. & KILBREATH, S. L. 2016. Diagnosis of upper limb lymphedema: development of an evidence-based approach. Acta Oncologica, 55, 1477-1483.

22. FERRARO, D., GOLDSTEIN, D., O’CONNELL, R. L., ZALCBERG, J. R., SJOQUIST, K. M., TEBBUTT, N. C., GRIMISON, P., MCLACHLAN, S., LIPTON, L. L., VASEY, P., GEBSKI, V. J., AIKEN, C., CRONK, M., NG, S., KARAPETIS, C. S. & SHANNON, J. 2016. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 78, 361-7.

23. GASTON, C. L., GRIMER, R. J., PARRY, M., STACCHIOTTI, S., DEI TOS, A. P., GELDERBLOM, H., FERRARI, S., BALDI, G. G., JONES, R. L., CHAWLA, S., CASALI, P., LECESNE, A., BLAY, J. Y., DIJKSTRA, S. P., THOMAS, D. M. & RUTKOWSKI, P. 2016. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res, 6, 15.

24. HIRSCH, F. R., GOVINDAN, R., ZVIRBULE, Z., BRAITEH, F., RITTMEYER, A., BELDA-INIESTA, C., ISLA, D., COSGRIFF, T., BOYER, M., UEDA, M., PHAN, S. & GANDARA, D. R. 2016. Efficacy and safety results from a Phase II, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy for advanced squamous cell non-small-cell lung cancer. Clinical Lung Cancer, 18, 43-49.

25. HODA, M. A., DONG, Y., ROZSAS, A., KLIKOVITS, T., LASZLO, V., GHANIM, B., STOCKHAMMER, P., OZSVAR, J.,

JAKOPOVIC, M., SAMARZIJA, M., BRCIC, L., BENDEK, M., SZIRTES, I., REID, G., KIRSCHNER, M. B., KAO, S. C., OPITZ, I., WEDER, W., FRAUENFELDER, T., NGUYEN-KIM, T. D., AIGNER, C., KLEPETKO, W., VAN ZANDWIJK, N., BERGER, W., DOME, B., GRUSCH, M. & HEGEDUS, B. 2016. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer, 63, 64-73.

26. HOLLESTELLE, A., VAN DER BAAN, F. H., BERCHUCK, A., JOHNATTY, S. E., ABEN, K. K., AGNARSSON, B. A., AITTOMAKI, K., ALDUCCI, E., ANDRULIS, I. L., ANTON-CULVER, H., ANTONENKOVA, N. N., ANTONIOU, A. C., APICELLA, C., ARNDT, V., ARNOLD, N., ARUN, B. K., ARVER, B., ASHWORTH, A., BAGLIETTO, L., BALLEINE, R., BANDERA, E. V., BARROWDALE, D., BEAN, Y. T., BECKMANN, L., BECKMANN, M. W., BENITEZ, J., BERGER, A., BERGER, R., BEUSELINCK, B., BISOGNA, M., BJORGE, L., BLOMQVIST, C., BOGDANOVA, N. V., BOJESEN, A., BOJESEN, S. E., BOLLA, M. K., BONANNI, B., BRAND, J. S., BRAUCH, H., BRENNER, H., BRINTON, L., BROOKS-WILSON, A., BRUINSMA, F., BRUNET, J., BRUNING, T., BUDZILOWSKA, A., BUNKER, C. H., BURWINKEL, B., BUTZOW, R., BUYS, S. S., CALIGO, M. A., CAMPBELL, I., CARTER, J., CHANG-CLAUDE, J., CHANOCK, S. J., CLAES, K. B., COLLEE, J. M., COOK, L. S., COUCH, F. J., COX, A., CRAMER, D., CROSS, S. S., CUNNINGHAM, J. M., CYBULSKI, C., CZENE, K., DAMIOLA, F., DANSONKA-MIESZKOWSKA, A., DARABI, H., DE LA HOYA, M., DEFAZIO, A., DENNIS, J., DEVILEE, P., DICKS, E. M., DIEZ, O., DOHERTY, J. A., DOMCHEK, S. M., DORFLING, C. M., DORK, T., SILVA IDOS, S., DU BOIS, A., DUMONT, M., DUNNING, A. M., DURAN, M., EASTON, D. F., ECCLES, D., EDWARDS, R. P., EHRENCRONA, H., EJLERTSEN, B., EKICI, A. B., ELLIS, S. D., ENGEL, C., ERIKSSON, M., FASCHING, P. A., FELIUBADALO, L., FIGUEROA, J., FLESCH-JANYS, D., FLETCHER, O., FONTAINE, A., FORTUZZI, S., FOSTIRA, F., et al. 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141, 386-401.


27. HUMPHREY, E. S., SU, S. P., NAGRIAL, A. M., HOCHGRAFE, F., PAJIC, M., LEHRBACH, G. M., PARTON, R. G., YAP, A. S., HORVATH, L. G., CHANG, D. K., BIANKIN, A. V., WU, J. & DALY, R. J. 2016. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Molecular and Cellular Proteomics, 15, 2671-85.

28. JOHNSON, S., BUTOW, P., KERRIDGE, I. & TATTERSALL, M. 2016a. Advance care planning for cancer patients: a systematic review of perceptions and experiences of patients, families, and healthcare providers. Psycho-oncology, 25, 362-86.

29. JOHNSON, S., CLAYTON, J., BUTOW, P. N., SILVESTER, W., DETERING, K., HALL, J., KIELY, B. E., CEBON, J., CLARKE, S., BELL, M. L., STOCKLER, M., BEALE, P. & TATTERSALL, M. H. 2016b. Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial. BMJ Open, 6, e012387. *

30. KAGER, L., WHELAN, J., DIRKSEN, U., HASSAN, B., ANNINGA, J., BENNISTER, L., BOVEE, J., BRENNAN, B., BROTO, J. M., BRUGIERES, L., CLETON-JANSEN, A. M., COPLAND, C., DUTOUR, A., FAGIOLI, F., FERRARI, S., FIOCCO, M., FLEUREN, E., GASPAR, N., GELDERBLOM, H., GERRAND, C., GERSS, J., GONZATO, O., VAN DER GRAAF, W., HECKER-NOLTING, S., HERRERO-MARTIN, D., KLCO-BROSIUS, S., KOVAR, H., LADENSTEIN, R., LANCIA, C., LEDELEY, M. C., MCCABE, M. G., METZLER, M., MYKLEBOST, O., NATHRATH, M., PICCI, P., POTRATZ, J., REDINI, F., RICHTER, G. H. S., REINKE, D., RUTKOWSKI, P., SCOTLANDI, K., STRAUSS, S., THOMAS, D., TIRADO, O. M., TIRODE, F., VASSAL, G. & BIELACK, S. S. 2016. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res, 6, 3.

31. KALSBEEK, A. M., CHAN, E. F., GROGAN, J., PETERSEN, D. C.,

JARATLERDSIRI, W., GUPTA, R., LYONS, R. J., HAYNES, A. M., HORVATH, L. G., KENCH, J. G., STRICKER, P. D. & HAYES, V. M. 2016. Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging, 8, 2702-2712.

32. KAO, S. C. & BOYER, M. J. 2016. Evolving landscape of epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology, 34, 3233-3234.

33. KAO, S. C., KIRSCHNER, M. B., COOPER, W. A., TRAN, T., BURGERS, S., WRIGHT, C., KORSE, T., VAN DEN BROEK, D., EDELMAN, J., VALLELY, M., MCCAUGHAN, B., PAVLAKIS, N., CLARKE, S., MOLLOY, M. P., VAN ZANDWIJK, N. & REID, G. 2016. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114, 524-31.

34. KILBREATH, S. L., REFSHAUGE, K. M., BEITH, J. M., WARD, L. C., UNG, O. A., DYLKE, E. S., FRENCH, J. R., YEE, J., KOELMEYER, L. & GAITATZIS, K. 2016. Risk factors for lymphoedema in women with breast cancer: A large prospective cohort. Breast, 28, 29-36.

35. KING, M. T., COSTA, D. S., AARONSON, N. K., BRAZIER, J. E., CELLA, D. F., FAYERS, P. M., GRIMISON, P., JANDA, M., KEMMLER, G., NORMAN, R., PICKARD, A. S., ROWEN, D., VELIKOVA, G., YOUNG, T. A. & VINEY, R. 2016a. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Quality of Life Research, 25, 625-36.

36. KING, M. T., COSTA, D. S. J., AARONSON, N. K., BRAZIER, J. E., CELLA, D. F., FAYERS, P. M., GRIMISON, P., JANDA, M., KEMMLER, G., NORMAN, R., PICKARD, A. S., ROWEN, D., VELIKOVA, G., YOUNG, T. A. & VINEY, R. 2016b. Erratum to: QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Quality of Life Research, 25, 2683.

37. LAWRENCE, N., MARTIN, A., TONER, G., STOCKLER, M., BUIZEN,

L., THOMSON, D., GEBSKI, V., FRIEDLANDER, M., YEUNG, A., WONG, N., GURNEY, H., ROSENTHAL, M., SINGHAL, N., KICHENADASSE, G., WONG, S., LEWIS, C., VASEY, P. & GRIMISON, P. 2016. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 27, 2302-2303.

38. LEE, C. K., DAVIES, L., GEBSKI, V. J., LORD, S. J., DI LEO, A., JOHNSTON, S., GEYER, C., JR., CAMERON, D., PRESS, M. F., ELLIS, C., LOI, S., MARSCHNER, I., SIMES, J. & DE SOUZA, P. 2016. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. J Clin Oncol, 34, 936-44.

39. LIM, J., LOMAX, A. J., MCNEIL, C. & HARRISBERG, B. 2016. Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: A case report. Ocular Immunology and Inflammation, 1-4.

40. LIU, G., TU, D., LEWIS, M., CHENG, D., SULLIVAN, L. A., CHEN, Z., MORGEN, E., SIMES, J., PRICE, T. J., TEBBUTT, N. C., SHAPIRO, J. D., JEFFERY, G. M., MELLOR, J. D., MIKESKA, T., VIRK, S., SHEPHERD, L. E., JONKER, D. J., O’CALLAGHAN, C. J., ZALCBERG, J. R., KARAPETIS, C. S. & DOBROVIC, A. 2016a. Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clin Cancer Res, 22, 2435-44.

41. LIU, X., BEITH, J., LOW, S. K. & BODDY, A. V. 2016b. The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer. Pharmacogenomics.

42. LOMAX, A. J., BEITH, J., BHADRI, V., BOYER, M., GRIMISON, P., HORVATH, L. G., KAO, S., TATTERSALL, M., THOMAS, D. & MCNEIL, C. 2016a. Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris


O’Brien Lifehouse. Internal Medicine Journal, 46, 1392-1398.

43. LOMAX, A. J., GE, L., ANAND, S., MCNEIL, C. & LOWE, P. 2016b. Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. Australasian Journal of Dermatology.

44. LUK, P. P., WESTON, J. D., YU, B., SELINGER, C. I., EKMEJIAN, R., EVISTON, T. J., LUM, T., GAO, K., BOYER, M., O’TOOLE, S. A., CLARK, J. R. & GUPTA, R. 2016. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck, 38 Suppl 1, E1838-47. *

45. MCBRIDE, K. A., HALLOWELL, N., TATTERSALL, M. H., KIRK, J., BALLINGER, M. L., THOMAS, D. M., MITCHELL, G. & YOUNG, M. A. 2016a. Timing and context: important considerations in the return of genetic results to research participants. J Community Genet, 7, 11-20.

46. MCBRIDE, K. A., SCHLUB, T. E., BALLINGER, M. L., THOMAS, D. M. & TATTERSALL, M. H. 2016b. International survey of awareness of genetic risk in the clinical sarcoma community. Asia Pacific Journal of Clinical Oncology, 12, 133-42.

47. MCCAUGHAN, G. J., FULHAM, M. J., MAHAR, A., SOPER, J., HONG, A. M., STALLEY, P. D., TATTERSALL, M. H. & BHADRI, V. A. 2016. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. Journal of Hematology & Oncology, 9, 48.

48. MCNEIL, C. M. 2016. What Have We Got to Lose? Journal of Clinical Oncology, 34, 4443-4444.

49. MERCIECA-BEBBER, R., FRIEDLANDER, M., KOK, P. S., CALVERT, M., KYTE, D., STOCKLER, M. & KING, M. T. 2016. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Quality of Life Research, 25, 2457-65.

50. MOTH, E., MCLACHLAN, S. A., VEILLARD, A. S., MULJADI, N., HUDSON, M., STOCKLER, M. R. & BLINMAN, P. 2016. Patients’ preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-

cell lung cancer. Lung Cancer, 95, 8-14.

51. NGIOW, S. F., LOI, S., THOMAS, D. & SMYTH, M. J. 2016. Mouse Models of Tumor Immunotherapy. Adv Immunol, 130, 1-24.

52. OVARIAN CANCER ASSOCIATION CONSORTIUM, B. C. A. C., CONSORTIUM OF MODIFIERS OF, B., BRCA, HOLLESTELLE, A., VAN DER BAAN, F. H., BERCHUCK, A., JOHNATTY, S. E., ABEN, K. K., AGNARSSON, B. A., AITTOMAKI, K., ALDUCCI, E., ANDRULIS, I. L., ANTON-CULVER, H., ANTONENKOVA, N. N., ANTONIOU, A. C., APICELLA, C., ARNDT, V., ARNOLD, N., ARUN, B. K., ARVER, B., ASHWORTH, A., AUSTRALIAN OVARIAN CANCER STUDY, G., BAGLIETTO, L., BALLEINE, R., BANDERA, E. V., BARROWDALE, D., BEAN, Y. T., BECKMANN, L., BECKMANN, M. W., BENITEZ, J., BERGER, A., BERGER, R., BEUSELINCK, B., BISOGNA, M., BJORGE, L., BLOMQVIST, C., BOGDANOVA, N. V., BOJESEN, A., BOJESEN, S. E., BOLLA, M. K., BONANNI, B., BRAND, J. S., BRAUCH, H., BREAST CANCER FAMILY, R., BRENNER, H., BRINTON, L., BROOKS-WILSON, A., BRUINSMA, F., BRUNET, J., BRUNING, T., BUDZILOWSKA, A., BUNKER, C. H., BURWINKEL, B., BUTZOW, R., BUYS, S. S., CALIGO, M. A., CAMPBELL, I., CARTER, J., CHANG-CLAUDE, J., CHANOCK, S. J., CLAES, K. B., COLLEE, J. M., COOK, L. S., COUCH, F. J., COX, A., CRAMER, D., CROSS, S. S., CUNNINGHAM, J. M., CYBULSKI, C., CZENE, K., DAMIOLA, F., DANSONKA-MIESZKOWSKA, A., DARABI, H., DE LA HOYA, M., DEFAZIO, A., DENNIS, J., DEVILEE, P., DICKS, E. M., DIEZ, O., DOHERTY, J. A., DOMCHEK, S. M., DORFLING, C. M., DORK, T., SILVA IDOS, S., DU BOIS, A., DUMONT, M., DUNNING, A. M., DURAN, M., EASTON, D. F., ECCLES, D., EDWARDS, R. P., EHRENCRONA, H., EJLERTSEN, B., EKICI, A. B., ELLIS, S. D., EMBRACE, ENGEL, C., ERIKSSON, M., FASCHING, P. A., FELIUBADALO, L., et al. 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecological Oncology, 141, 386-401.

53. PARK, K., TAN, E. H., O’BYRNE, K., ZHANG, L., BOYER, M., MOK, T., HIRSH, V., YANG, J. C., LEE, K. H., LU, S., SHI, Y., KIM, S. W., LASKIN, J., KIM, D. W., ARVIS, C. D., KOLBECK, K., LAURIE, S. A., TSAI, C. M., SHAHIDI, M., KIM, M., MASSEY, D., ZAZULINA, V. & PAZ-ARES, L. 2016a. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, 17, 577-89.

54. PARK, K., TAN, E. H., ZHANG, L., HIRSH, V., O’BYRNE, K., BOYER, M., YANG, J., MOK, T., KIM, M. & PAZ-ARES, L. 2016b. 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. Journal of Thoracic Oncology, 11, S117-8.

55. PAVLAKIS, N., SJOQUIST, K. M., MARTIN, A. J., TSOBANIS, E., YIP, S., KANG, Y. K., BANG, Y. J., ALCINDOR, T., O’CALLAGHAN, C. J., BURNELL, M. J., TEBBUTT, N. C., RHA, S. Y., LEE, J., CHO, J. Y., LIPTON, L. R., WONG, M., STRICKLAND, A., KIM, J. W., ZALCBERG, J. R., SIMES, J. & GOLDSTEIN, D. 2016. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol, 34, 2728-35.

56. PULVIRENTI, T., HONG, A., CLEMENTS, A., FORSTNER, D., SUCHOWERSKY, A., GUMINSKI, A., MCNEIL, C., HERSEY, P., FOGARTY, G., KEFFORD, R., LONG, G. V. & WANG, W. 2016. Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34, e17-20.

57. RAGIN, C., LIU, J. C., JONES, G., SHOYELE, O., SOWUNMI, B., KENNETT, R., GROEN, H. J., GIBBS, D., BLACKMAN, E., ESAN, M., BRANDWEIN, M. S., DEVARAJAN, K., BUSSU, F., CHERNOCK, R., CHIEN, C. Y., COHEN, M. A., SAMIR, E. M., MIKIO, S., D’SOUZA, G., FUNCHAIN, P., ENG, C., GOLLIN, S. M., HONG, A., JUNG, Y. S., KRUGER, M., LEWIS, J., JR., MORBINI, P., LANDOLFO, S., RITTA, M., STRAETMANS, J., SZARKA, K.,


TACHEZY, R., WORDEN, F. P., NELSON, D., GATHERE, S. & TAIOLI, E. 2016. Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients. Carcinogenesis. *

58. RAMALINGAM, S. S., O’BYRNE, K., BOYER, M., MOK, T., JANNE, P. A., ZHANG, H., LIANG, J., TAYLOR, I., SBAR, E. I. & PAZ-ARES, L. 2016. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology, 27, 423-9.

59. REBBECK, T. R., FRIEBEL, T. M., MITRA, N., WAN, F., CHEN, S., ANDRULIS, I. L., APOSTOLOU, P., ARNOLD, N., ARUN, B. K., BARROWDALE, D., BENITEZ, J., BERGER, R., BERTHET, P., BORG, A., BUYS, S. S., CALDES, T., CARTER, J., CHIQUETTE, J., CLAES, K. B., COUCH, F. J., CYBULSKI, C., DALY, M. B., DE LA HOYA, M., DIEZ, O., DOMCHEK, S. M., NATHANSON, K. L., DURDA, K., ELLIS, S., EVANS, D. G., FORETOVA, L., FRIEDMAN, E., FROST, D., GANZ, P. A., GARBER, J., GLENDON, G., GODWIN, A. K., GREENE, M. H., GRONWALD, J., HAHNEN, E., HALLBERG, E., HAMANN, U., HANSEN, T. V., IMYANITOV, E. N., ISAACS, C., JAKUBOWSKA, A., JANAVICIUS, R., JAWORSKA-BIENIEK, K., JOHN, E. M., KARLAN, B. Y., KAUFMAN, B., INVESTIGATORS, K., KWONG, A., LAITMAN, Y., LASSET, C., LAZARO, C., LESTER, J., LOMAN, N., LUBINSKI, J., MANOUKIAN, S., MITCHELL, G., MONTAGNA, M., NEUHAUSEN, S. L., NEVANLINNA, H., NIEDERACHER, D., NUSSBAUM, R. L., OFFIT, K., OLAH, E., OLOPADE, O. I., PARK, S. K., PIEDMONTE, M., RADICE, P., RAPPAPORT-FUERHAUSER, C., ROOKUS, M. A., SEYNAEVE, C., SIMARD, J., SINGER, C. F., SOUCY, P., SOUTHEY, M., STOPPA-LYONNET, D., SUKIENNICKI, G., SZABO, C. I., TANCREDI, M., TEIXEIRA, M. R., TEO, S. H., TERRY, M. B., THOMASSEN, M., TIHOMIROVA, L., TISCHKOWITZ, M., TOLAND, A. E., TOLOCZKO-GRABAREK, A., TUNG, N., VAN RENSBURG, E. J., VILLANO, D., WANG-GOHRKE, S., WAPPENSCHMIDT, B., WEITZEL, J. N., ZIDAN, J., ZORN, K. K., MCGUFFOG, L., EASTON, D., et al. 2016. Inheritance of deleterious mutations at both

BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 18, 112.

60. REDFERN, A., BURSLEM, K., WOODWARD, N., BEITH, J., MCCARTHY, N., DE BOER, R. & BELL, R. 2016. Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. Asia-Pacific Journal of Clinical Oncology, 12 Suppl 1, 19-31.

61. REID, G., KAO, S. C., PAVLAKIS, N., BRAHMBHATT, H., MACDIARMID, J., CLARKE, S., BOYER, M. & VAN ZANDWIJK, N. 2016. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 8, 1079-85.

62. RONCOLATO, F. T., CHATFIELD, M., HOUGHTON, B., TONER, G., STOCKLER, M., THOMSON, D., FRIEDLANDER, M., GURNEY, H., ROSENTHAL, M., GRIMISON, P., AUSTRALIAN & NEW ZEALAND UROGENITAL PROSTATE CANCER TRIALS, G. 2016. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Internal Medicine Journal, 46, 893-8.

63. SATGUNASEELAN, L., GUPTA, R., MADORE, J., CHIA, N., LUM, T., PALME, C. E., BOYER, M., SCOLYER, R. A. & CLARK, J. R. 2016. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 48, 574-80. *

64. SCHOFIELD, P. E., STOCKLER, M. R., ZANNINO, D., TEBBUTT, N. C., PRICE, T. J., SIMES, R. J., WONG, N., PAVLAKIS, N., RANSOM, D., MOYLAN, E., UNDERHILL, C., WYLD, D., BURNS, I., WARD, R., WILCKEN, N. & JEFFORD, M. 2016. Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Supportive Care in Cancer, 24, 401-8.

65. SEGELOV, E., THAVANESWARAN, S., WARING, P. M., DESAI, J., ROBLEDO, K. P., GEBSKI, V. J., ELEZ, E., NOTT, L. M., KARAPETIS, C. S., LUNKE, S., CHANTRILL, L. A., PAVLAKIS, N., KHASRAW, M., UNDERHILL, C., CIARDIELLO, F., JEFFORD, M., WASAN,

H., HAYDON, A., PRICE, T. J., VAN HAZEL, G., WILSON, K., SIMES, J. & SHAPIRO, J. D. 2016. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. J Clin Oncol, 34, 2258-64.

66. SHAW, J. M., PRICE, M. A., CLAYTON, J. M., GRIMISON, P., SHAW, T., RANKIN, N. & BUTOW, P. N. 2016. Developing a clinical pathway for the identification and management of anxiety and depression in adult cancer patients: an online Delphi consensus process. Supportive Care in Cancer, 24, 33-41.

67. SMITH, A. B., BUTOW, P., OLVER, I., LUCKETT, T., GRIMISON, P., TONER, G. C., STOCKLER, M. R., HOVEY, E., STUBBS, J., TURNER, S., HRUBY, G., GURNEY, H., ALAM, M., COX, K. & KING, M. T. 2016. The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship: Research and Practice, 10, 223-33. *

68. SUNDARESAN, P., KING, M., STOCKLER, M., COSTA, D. & MILROSS, C. 2016a. Barriers to radiotherapy utilization: Consumer perceptions of issues influencing radiotherapy-related decisions. Asia Pacific Journal of Clinical Oncology. *

69. SUNDARESAN, P., MILROSS, C. G., STOCKLER, M. R., COSTA, D. S. & KING, M. T. 2016b. Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues. Quality of Life Research, 25, 2361-6. *

70. SUNDARESAN, P., STOCKLER, M. R. & MILROSS, C. G. 2016c. What is access to radiation therapy? A conceptual framework and review of influencing factors. Australian Health Review, 40, 11-8. *

71. TATTERSALL, M. H. N. 2016. Ethical issues around Phase I and Phase III clinical trials in cancer. Cancer Forum, 40, 128-131.


72. THOMAS, D. M. & BALLINGER, M. L. 2016. Diagnosis and Management of Hereditary Sarcoma. Recent Results Cancer Res, 205, 169-89.

73. VAN GELDERMALSEN, M., WANG, Q., NAGARAJAH, R., MARSHALL, A. D., THOENG, A., GAO, D., RITCHIE, W., FENG, Y., BAILEY, C. G., DENG, N., HARVEY, K., BEITH, J. M., SELINGER, C. I., O’TOOLE, S. A., RASKO, J. E. & HOLST, J. 2016. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene, 35, 3201-8.

74. VARGAS, A. C., SELINGER, C. I., SATGUNASEELAN, L., COOPER, W. A., GUPTA, R., STALLEY, P., BROWN, W., SOPER, J., SCHATZ, J., BOYLE, R., THOMAS, D. M., TATTERSALL, M. H., BHADRI, V. A., MACLEAN, F., BONAR, S. F., SCOLYER, R. A., KARIM, R. Z., MCCARTHY, S. W., MAHAR, A. & O’TOOLE, S. A. 2016. Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69, 1000-1011. *

75. WARRIER, S., TAPIA, G., GOLTSMAN, D. & BEITH, J. 2016. An update in breast cancer screening and management. Women’s Health, 12, 229-39. *

76. WARTON, K., MAHON, K. L. & SAMIMI, G. 2016. Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocrine-Related Cancer, 23, R157-71.

Note: *publication shared with another

department

Grants

1. Agar M, Vardy J, Koh E, Simes R, Nowak A, Wheeler H, Barnes E, Hovey E. The ACED trial: a phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive high-grade glioma requiring treatment with dexamethasone. Cancer Australia. (2016).

2. Anderson RL, Swarbrick A, Johnstone R, Chua B, Gill A, Khanna K, Lakhani S, Loi S, O’Toole S, Saunders C. AI: Beith J. Development of a national resource of primary and secondary metastatic breast cancers to test new drugs and identify the genetic changes that drive breast cancer growth and metastasis. National Breast Cancer Foundation (NBCF) National Infrastructure Grant. $1,834,335 (2015-2019).

3. Barratt A, McCaffery K, Carter S, Glasziou P, Kerridge I, Semsarian C, Howard K, Doust J, Elshaug A, Moynihan R. AI: Tattersall MHN. Creating sustainable healthcare: ensuring new diagnostics avoid harms, improve outcomes, and direct resources wisely. APP1104136 (CRE in Health Services Research funding). $2,497,658 (2015-2019).

4. Butler L, Hoy A, Swinnen J, Wittert G, Scott A, Tilley W. (team leaders). Mahon K and Horvath L (team members). Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. Movember Revolutionary Team Award. $3 million (2015-2018).

5. Butler L, Horvath L, Tilley W, Stricker P. A pharmacodynamics study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. 1050880. Cancer Australia/Prostate Cancer Foundation of Australia. $590.000. (2013-2018, 2 year extension).

6. Butow P, Andrews G, Kelly B, Girgis A, Aranda S, Viney R, Clayton J, Hack T, Price MA, Beale P. AI: Grimison P. A sustainable and supported clinical pathway for managing anxiety and depression in cancer patients: developing and evaluating components and testing implementation strategies. Cancer Institute NSW Program Grant for Excellence in Translational Research. $3,643,992. (2015-2019).

7. Dinger M, Mattick J, Thomas DM. Sydney Genomics Collaborative Medical Genome Reference Bank. NSW Office for Health and Medical Research (OHMR). $10,000,000. (2014-2018).

8. Goldstein D, Friedlander M, Kiernan M, Krishnan A, Boyle F, Moalem-Taylor G, Haas M, Cohn R, Farrar M. AI: Grimison P .Chemotherapy-induced peripheral neuropathy: assessment strategies, treatments and risk factors. Cancer Institute NSW Program Grant for Excellence in Translational Research. $3,040,000. (2015-2019).

9. Grimison P, Toner G, Stockler M, Friedlander M, Thomson D, Gebski V, King M, Quinn D, Singhal N. Accelerating first-line chemotherapy to improve cure rates for advanced germ cell tumours: an Australian-led, international randomised trial. Cancer Australia and Cancer Council Australia Project Grant. $595,342.

10. Haydon A, Segelov E, Zalcberg J, Simes R, Walpole E, Yip D, Price T, Jefford M. Short Course Oncology Therapy (SCOT) - a study of adjuvant chemotherapy in colorectal cancer. Cancer Australia. (2015-2016).

11. Horvath LG, Exploiting lipid metabolism to predict response to treatment in advanced prostate cancer. Peer-reviewed Astellas research project grant. $200,000. (2016-2018).

12. Hovey E, Simes R, Koh E, Agar M, McDonald K, Wheeler H. Cooperative Trials Group for Neuro-Oncology (COGNO) infrastructure funding for support, development and conduct of clinical trials and translational research. Cancer Australia (2013-2016).

13. Kao S, Boyer M, Cooper W, Beale P. Sydney Catalyst top-down funding 2015: Lung cancer cohort - a platform to study serial biospecimens and matched clinical data (LC-PLAT Study). $150,000. (2015-2016).

14. Khasraw M (Principal), Simes R. VEliparib, Radiotherapy and Temozolomide trial in Unmethylated (VERTU) MGMT glioblastoma. Cooperative Trials Group for Neuro- Oncology (COGNO). Cure Brain Cancer Foundation. (2014-2016).

15. Lacey J, McNeil C, Dhillon H, Marthick M, Kao S (Investigators). MSD grant: Living well with immunotherapy for melanoma. $122,896. (2015-2016).


16. Lindeman G, Mann G, Desai J, Forbes J, Fox S, Liew D, Mcarthur G, Simes J, Sutherland R, Visvader J. Centre of Research Excellence for Translational Breast Cancer Research: from discovery to better health outcomes (2012-2016).

17. Mahon K. Movember Prostate Cancer Foundation of Australia Clinician Scientist award. $450,000. (2016-2018).

18. Nowak A, Rosenthal M, Simes R, Ryan G, Drummond K Phase III trial of concurrent and adjuvant temozolomide chemotherapy in non- 1p/19q deleted anaplastic glioma. Cancer Australia. (2015-2018).

19. Segelov E, Simes J, Tebbutt N, Zalcberg J, Sommeijer D, Chia J. ASCOLT trial: aspirin for Dukes C and high-risk Dukes B colorectal cancers. An international, multi-centre, double blind, randomised trial. Cancer Australia. (2014-2016).

20. Simes J, Boyer MJ, Solomon M, Sutherland R, Butow P, Vadas M. Cancer Institute NSW Translational Cancer Research Centre Grant, $6,500,000 (2011-2016).

21. Simes J, Keech A, Gebski A, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner I. Advancing the evidence base for care and policy in priority health areas. NHMRC program grant (2013-2016).

22. Simes J. NHMRC Senior Principal Research Fellowship, (2012-2016).

23. Simes R. Phase II randomised non-comparative placebo-controlled double blind trial of acetazolamide plus dexamethasone versus dexamethasone alone for management of cerebral oedema in recurrent and/or progressive high grade glioma. ACED. Cooperative Trials Group for Neuro-Oncology (COGNO). Cure Brain Cancer Foundation (Harry Secombe Foundation). (2015-2016).

24. Simes R, CONTROL NETs: Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study, Unicorn Foundation. (2015-2016).

25. Stricker PD, Clark SJ, Hayes VM, Horvath LG, Kench JG, Mattick JS, Rasiah K. The Kinghorn Cancer Centre Australian Prostate Cancer Research Centre. $5.463 million. Australian Government Department of Health and Aging (2013-2016).

26. Thomas DM. Genomic cancer medicine. NHMRC Principal Research Fellowship. $753,300. (2010-2016).

27. Thomas D and Horvath LG. Cancer Gene Discovery and Validation Program. RT Hall Foundation. $334,425. (2016-2018).

28. Thomas DM, Simes J, Cowley M, Dinger M, Epstein R, Goldstein D, Goodwin A, Horvath LG, Jacobs C, Kirk J, Lee C, Mann G, Marshall G, Meiser B, Meldrum C, Newson A, Orchard P, O’Toole SA, Roscioli T, Sjoquist K, Spigelman A. Translating genomics into health outcomes: a genomic cancer medicine program. NSW Office for Health and Medical Research (OHMR). $6,790,082. (2014-2018). *

29. van Zandwijk N, Reid G, Vardy J, Kao S, Pavlakis N. Translating malignant mesothelioma research into better outcomes for patients and their families. Cancer Institute NSW Translational Program Grant. $3,500,000. (2012-2016).

30. von Itzstein M and Horvath LG. The Cancer Glycome Project. Peer-reviewed grant from private foundation. $2.54 million. (2016-2016).

31. White K, McKenzie H, Hayes L, Simpson J, Horvath L, Willcock S, Cox K, Fethney J. Improving outcomes for patients receiving outpatient chemotherapy through a shared care pathway intervention. NHMRC project grant. (2013-2016).

Note: *grant shared with another department

Radiation Oncology Publications

1. BENNETT, M. H., FELDMEIER, J., HAMPSON, N. B., SMEE, R. & MILROSS, C. 2016. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database of Systematic Reviews, 4, CD005005.

2. BUTSON, M., CHEN, T., ALZAIDI, S., POPE, D., BUTSON, E., GORJIARA, T., PODER, J., CHO, G., GILL, S. & MORALES, J. 2016a. Extrapolated skin dose assessment with optically stimulated luminscent dosimeters. Biomedical Physics and Engineering Express, 2, 047001.

3. BUTSON, M., POPE, D., HAQUE, M., CHEN, T., SONG, G. & WHITAKER, M. 2016b. Build-up material requirements in clinical dosimetry during total body irradiation treatments. Journal of Medical Physics, 41, 149-52.

4. CHOONG, E. S., HRUBY, G., YANG, J., KWONG, C. & PATANJALI, N. 2016. 78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients. Asia Pac J Clin Oncol.

5. ECCLES, C. L., TSE, R. V., HAWKINS, M. A., LEE, M. T., MOSELEY, D. J. & DAWSON, L. A. 2016. Intravenous contrast-enhanced con beam CT (IVCBCT) of intrahepatic tumours and vessels. Advances in Radiation Oncology, 1, 43-50.

6. GEE, H. E., BIGNELL, F., ODGERS, D., GILL, S., MARTIN, D., TOOHEY, J. & CARROLL, S. 2016. In vivo dosimetric impact of breast tissue expanders on post-mastectomy radiotherapy. Journal of Medical Imaging and Radiation Oncology, 60, 138-45.

7. HONG, A., LEE, C. S., JONES, D., VEILLARD, A. S., ZHANG, M., ZHANG, X., SMEE, R., CORRY, J., PORCEDDU, S., MILROSS, C., ELLIOTT, M., CLARK, J. & ROSE, B. 2016a. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head & Neck, 38, 743-50. *

8. HONG, A., ZHANG, X., JONES, D., VEILLARD, A. S., ZHANG, M., MARTIN, A., LYONS, J. G., LEE, C. S. & ROSE, B. 2016b. Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 118, 342-9.*

9. HONG, A., ZHANG, X., JONES, D., ZHANG, M., LEE, C. S., LYONS, J. G., VEILLARD, A. S. & ROSE, B. 2016c. E6 viral protein ratio correlates with


outcomes in human papillomavirus related oropharyngeal cancer. Cancer Biology and Therapy, 17, 181-7. *

10. JABBOUR, J., EBRAHIMI, A., SHEPHERD, H., MILROSS, C., SUNDARESAN, P., DHILLON, H. & CLARK, J. R. 2016a. Head and neck cancer patient education and support needs--A multi-institution survey. Cancer, in press.*

11. JABBOUR, J., SHEPHERD, H., MILROSS, C., SUNDARESAN, P., CLARK, J. R. & DHILLON, H. 2016b. Challenges in producing tailored internet patient education materials. International Journal of Radiation Oncology, Biology, Physics, in press. *

12. JAMESON, M. G., MCNAMARA, J., BAILEY, M., METCALFE, P. E., HOLLOWAY, L. C., FOO, K., DO, V., MILESHKIN, L., CREUTZBERG, C. L. & KHAW, P. 2016. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. Journal of Medical Imaging and Radiation Oncology, 60, 554-9.

13. LAI, K., KILLINGSWORTH, M., MATTHEWS, S., CAIXEIRO, N., EVANGELISTA, C., WU, X., WYKES, J., SAMAKEH, A., FORSTNER, D., NILES, N., HONG, A. & LEE, C. S. 2016. Differences in survival outcome between oropharyngeal and oral cavity squamous cell carcinoma in relation to HPV status. Journal of Oral

Pathology and Medicine.

14. LOW, T. H., GAO, K., GUPTA, R., CLIFFORD, A., ELLIOTT, M., CH’NG, S., MILROSS, C. & CLARK, J. R. 2016. Factors predicting poor outcomes in T1N0 oral squamous cell carcinoma: indicators for treatment intensification. Australian and New Zealand Journal of

Surgery, 86, 366-71.*

15. MORALES, J. E., BUTSON, M., CROWE, S. B., HILL, R. & TRAPP, J. V. 2016. An experimental extrapolation technique using the Gafchromic EBT3 film for relative output factor measurements in small x-ray fields. Medical Physics, 43, 4687.

16. NAEHRIG, D. N., KOH, E. S., VOGIATZIS, M., YANAGISAWA, W., KWONG, C., SHEPHERD, H. L., MILROSS, C. & DHILLON, H. M. 2016. Impact of cognitive function on communication in patients with primary or secondary brain tumours. Journal of Neurooncology, 126, 299-307.

17. PODER, J. & WHITAKER, M. 2016. Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements. Journal of Contemporary Brachytherapy, 8, 201-7.

18. RAGIN, C., LIU, J. C., JONES, G., SHOYELE, O., SOWUNMI, B., KENNETT, R., GROEN, H. J., GIBBS, D., BLACKMAN, E., ESAN, M., BRANDWEIN, M. S., DEVARAJAN, K., BUSSU, F., CHERNOCK, R., CHIEN, C. Y., COHEN, M. A., SAMIR, E. M., MIKIO, S., D’SOUZA, G., FUNCHAIN, P., ENG, C., GOLLIN, S. M., HONG, A., JUNG, Y. S., KRUGER, M., LEWIS, J., JR., MORBINI, P., LANDOLFO, S., RITTA, M., STRAETMANS, J., SZARKA, K., TACHEZY, R., WORDEN, F. P., NELSON, D., GATHERE, S. & TAIOLI, E.

Marc Monsell, Assistant Director of Nursing checking theatre equipment


2016. Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis.*

19. SMITH, A. B., BUTOW, P., OLVER, I., LUCKETT, T., GRIMISON, P., TONER, G. C., STOCKLER, M. R., HOVEY, E., STUBBS, J., TURNER, S., HRUBY, G., GURNEY, H., ALAM, M., COX, K. & KING, M. T. 2016a. The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. Journal of Cancer Survivorship: Research and Practice, 10, 223-33.*

20. SMITH, S., ESTOESTA, R. P., KADER, J. A., MARTIN, D., CLARIDGE-MACKONIS, E. R., TOOHEY, J. M. & CARROLL, S. L. 2016b. Hybrid intensity-modulated radiation therapy (IMRT) simultaneous integrated boost (SIB) technique versus three-dimensional (3D) conformal radiotherapy with SIB for breast radiography: a planning comparison. Journal of Radiotherapy in Practice, 15, 131-142.

21. SMITH, S. K., YAN, B., MILROSS, C. & DHILLON, H. M. 2016c. Radiation therapy for people with cancer: what do written information materials tell them? European Journal of Cancer Care, 25, 675-85.

22. SUNDARESAN, P., KING, M., STOCKLER, M., COSTA, D. & MILROSS, C. 2016a. Barriers to radiotherapy utilization: Consumer perceptions of issues influencing radiotherapy-related decisions. Asia Pacific Journal of Clinical Oncology.*

23. SUNDARESAN, P., MILROSS, C. G., STOCKLER, M. R., COSTA, D. S. & KING, M. T. 2016b. Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues. Quality of Life Research, 25, 2361-6.*

24. SUNDARESAN, P., STOCKLER, M. R. & MILROSS, C. G. 2016c. What is access to radiation therapy? A conceptual framework and review of influencing factors. Australian Health Review, 40, 11-8.*


department

Grants

1. Fogarty G, Hong A, Burmeister B, Drummond K, Thompson J, Dolven Jacobsen K. ANZMTG 01.07 WBRTMel: Whole brain radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial; Cancer Australia (2015-2018)

2. Grulich A et al. AI: Carroll S. NSW Cancer Council STREP grants. Preventing morbidity and mortality from anal cancer (P-MMAC). (2011-2016)

3. Guitera P, Kelly J, Fogarty G, Hong A, Foote M, Soyer H, Stretch J, Shannon K, Ruben J. ANZMTG 02.12 A randomised controlled multi-centre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5 mm margins is not possible, is refused, or fails (RADICAL). Cancer Australia.(2015-2018)

Breast Surgery Publications 1. ANG, S. C., TAPIA, G., DAVIDSON, E. J., KAHRAMANGIL, B., MAK, C., CARMALT, H. & WARRIER, S. 2016. Positive anterior margins in breast conserving surgery: Does it matter? A systematic review of the literature. Breast, 27, 105-8.

2. BECKERS, R. K., SELINGER, C. I., VILAIN, R., MADORE, J., WILMOTT, J. S., HARVEY, K., HOLLIDAY, A., COOPER, C. L., ROBBINS, E., GILLETT, D., KENNEDY, C. W., GLUCH, L., CARMALT, H., MAK, C., WARRIER, S., GEE, H. E., CHAN, C., MCLEAN, A., WALKER, E., MCNEIL, C. M., BEITH, J. M., SWARBRICK, A., SCOLYER, R. A. & O’TOOLE, S. A. 2016. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69, 25-34.*

3. BRENNAN, M. E., FLITCROFT, K., WARRIER, S., SNOOK, K. & SPILLANE, A. J. 2016. Immediate expander/implant breast reconstruction followed by post-mastectomy radiotherapy for breast cancer: Aesthetic, surgical, satisfaction and quality of life outcomes in women with high-risk breast cancer. Breast, 30, 59-65.

4. CHEONG, J. Y., GOLTSMAN, D. & WARRIER, S. 2016. A new method of salvaging breast reconstruction after breast implant using negative pressure wound therapy and instillation. Aesthetic and Plastic Surgery, 40, 745-8.

5. WARRIER, S., TAPIA, G., GOLTSMAN, D. & BEITH, J. 2016. An update in breast cancer screening and management. Women’s Health, 12, 229-39. *


department

Grants

1. O’Toole S. 2016 National Breast Cancer Foundation Practitioner Fellowship. Based around multidisciplinary breast cancer team at RPA and Lifehouse. $700,000 (2016-2020).

2. Thomas DM, Simes J, Cowley M, Dinger M, Epstein R, Goldstein D, Goodwin A, Horvath LG, Jacobs C, Kirk J, Lee C, Mann G, Marshall G, Meiser B, Meldrum C, Newson A, Orchard P, O’Toole SA, Roscioli T, Sjoquist K, Spigelman A. Translating genomics into health outcomes: a genomic cancer medicine program. NSW Office for Health and Medical Research (OHMR). $6,790,082. (2014-2018). *

Note: *grant shared with another department

Gynaecological Oncology Publications

1. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme. Clinical question: Diagnosis of high-grade squamous abnormalities . NHMRC in press

2. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme Guidelines: Cervical cancer/Screening/Discussion HSIL — NHMRC in press

3. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme Clinical question: Follow-up of high grade squamous lesions


post-treatment: cytology and HPV testing at 12 vs at 12 and 24 mo (body of evidence· screen literature updates )— NHMRC in press

4. ANDERSON L., GARRET A., HAMMOND I. & PATHER S. National Cervical Screening Programme. Clinical question: Management of low-grade cervical squamous abnormalities in HPV-positive women. NHMRC in press

5. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme Clinical question: Test of Cure after treatment for HSIL (CIN2 3) (body of evidence· screen literature updates ). NHMRC in Press

6. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme Clinical question: Treatment of high-grade squamous abnormalities (body of evidence· screen literature updates )— NHMRC in press

7. ANDERSON L., HAMMOND I., PATHER S., WREDE D. & WRIGHT H. Guidelines: Cervical cancer/Screening/Management of glandular abnormalities — NHMRC in Press.

8. ANDERSON L., PATHER S., WRIGHT G., HAMMOND I. & SAVILLE M. National Cervical Screening Programme Guidelines: Cervical cancer/Screening/Management histologically confirmed high-grade squamous abnormalities. NHMRC in press

9. BRAND A., HAMMOND I., PATHER S., ROESKE L. & WREDE D. National Cervical Screening Programme. Screening in immune-deficient women . NHMRC in press.

10. BLAIN, G., RICHARDS, A., PATHER, S., CARTER, J. & SAIDI, S. 2016. A retrospective observational study for the outcomes of women presenting to a colposcopy clinic with a high-grade Pap smear - Implications for a ‘see and treat’ approach to management. Australian & New Zealand Journal of Obstetrics &

Gynaecology, 56, 207-11.

11. CARTER, J. 2016. The renewal of the National Cervical Screening Program. Medical Journal of Australia, 205, 357-358.

12. CARTER, J., PHILP, S. & WAN, K. M. 2016. Optimising recovery after surgery: Predictors of early discharge and hospital readmission. The Australian & New Zealand Journal of Obstetrics & Gynaecology, 56, 489-495.

13. DAVIS, G., ANDERSON, L. & PATHER, S. 2016. Extramammary Paget’s disease mimicking localized malignancy on cervical cytology. Diagnostic Cytopathology, 44, 931-934.

14. FARRELL, R., DIXON, S. G., CARTER, J. & WEBB, P. M. 2016. Lymphadenectomy in early-stage intermediate/high-risk endometrial cancer: Clinical characteristics and outcomes in an Australian cohort. International Journal of Gynecological Cancer, in press.

15. MITTAL, P., KLINGLER-HOFFMANN, M., ARENTZ, G., WINDERBAUM, L.,

Martin Hines, Technical Officer, removing tissue samples from a cryotank


KAUR, G., ANDERSON, L., SCURRY, J., LEUNG, Y., STEWART, C. J., CARTER, J., HOFFMANN, P. & OEHLER, M. K. 2016a. Annexin A2 and alpha actinin 4 expression correlates with metastatic potential of primary endometrial cancer. Biochimica et Biophysica Acta.

16. MITTAL, P., KLINGLER-HOFFMANN, M., ARENTZ, G., WINDERBAUM, L., LOKMAN, N. A., ZHANG, C., ANDERSON, L., SCURRY, J., LEUNG, Y., STEWART, C. J., CARTER, J., KAUR, G., OEHLER, M. K. & HOFFMANN, P. 2016b. Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging. Proteomics, 16, 1793-801.

17. MORTON, R., ANDERSON, L., CARTER, J., PATHER, S. & SAIDI, S. 2016. Intraoperative frozen section of ovarian tumors: A 6-year review of performance and potential pitfalls in an Australian tertiary referral center. International Journal of Gynecological Cancer.

18. OVARIAN CANCER ASSOCIATION CONSORTIUM, B. C. A. C., CONSORTIUM OF MODIFIERS OF, B., BRCA, HOLLESTELLE, A., VAN DER BAAN, F. H., BERCHUCK, A., JOHNATTY, S. E., ABEN, K. K., AGNARSSON, B. A., AITTOMAKI, K., ALDUCCI, E., ANDRULIS, I. L., ANTON-CULVER, H., ANTONENKOVA, N. N., ANTONIOU, A. C., APICELLA, C., ARNDT, V., ARNOLD, N., ARUN, B. K., ARVER, B., ASHWORTH, A., AUSTRALIAN OVARIAN CANCER STUDY, G., BAGLIETTO, L., BALLEINE, R., BANDERA, E. V., BARROWDALE, D., BEAN, Y. T., BECKMANN, L., BECKMANN, M. W., BENITEZ, J., BERGER, A., BERGER, R., BEUSELINCK, B., BISOGNA, M., BJORGE, L., BLOMQVIST, C., BOGDANOVA, N. V., BOJESEN, A., BOJESEN, S. E., BOLLA, M. K., BONANNI, B., BRAND, J. S., BRAUCH, H., BREAST CANCER FAMILY, R., BRENNER, H., BRINTON, L., BROOKS-WILSON, A., BRUINSMA, F., BRUNET, J., BRUNING, T., BUDZILOWSKA, A., BUNKER, C. H., BURWINKEL, B., BUTZOW, R., BUYS, S. S., CALIGO, M. A., CAMPBELL, I., CARTER, J., CHANG-CLAUDE, J., CHANOCK, S. J., CLAES, K. B., COLLEE,

J. M., COOK, L. S., COUCH, F. J., COX, A., CRAMER, D., CROSS, S. S., CUNNINGHAM, J. M., CYBULSKI, C., CZENE, K., DAMIOLA, F., DANSONKA-MIESZKOWSKA, A., DARABI, H., DE LA HOYA, M., DEFAZIO, A., DENNIS, J., DEVILEE, P., DICKS, E. M., DIEZ, O., DOHERTY, J. A., DOMCHEK, S. M., DORFLING, C. M., DORK, T., SILVA IDOS, S., DU BOIS, A., DUMONT, M., DUNNING, A. M., DURAN, M., EASTON, D. F., ECCLES, D., EDWARDS, R. P., EHRENCRONA, H., EJLERTSEN, B., EKICI, A. B., ELLIS, S. D., EMBRACE, ENGEL, C., ERIKSSON, M., FASCHING, P. A., FELIUBADALO, L., et al. 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecological Oncology, 141, 386-401.

19. PHILP, S., MELLON, A., BARNETT, C., D’ABREW, N. & WHITE, K. 2016. The road less travelled: Australian women’s experiences with vulval cancer. European Journal of Cancer Care, 26.

20. REBBECK, T. R., FRIEBEL, T. M., MITRA, N., WAN, F., CHEN, S., ANDRULIS, I. L., APOSTOLOU, P., ARNOLD, N., ARUN, B. K., BARROWDALE, D., BENITEZ, J., BERGER, R., BERTHET, P., BORG, A., BUYS, S. S., CALDES, T., CARTER, J., CHIQUETTE, J., CLAES, K. B., COUCH, F. J., CYBULSKI, C., DALY, M. B., DE LA HOYA, M., DIEZ, O., DOMCHEK, S. M., NATHANSON, K. L., DURDA, K., ELLIS, S., EVANS, D. G., FORETOVA, L., FRIEDMAN, E., FROST, D., GANZ, P. A., GARBER, J., GLENDON, G., GODWIN, A. K., GREENE, M. H., GRONWALD, J., HAHNEN, E., HALLBERG, E., HAMANN, U., HANSEN, T. V., IMYANITOV, E. N., ISAACS, C., JAKUBOWSKA, A., JANAVICIUS, R., JAWORSKA-BIENIEK, K., JOHN, E. M., KARLAN, B. Y., KAUFMAN, B., INVESTIGATORS, K., KWONG, A., LAITMAN, Y., LASSET, C., LAZARO, C., LESTER, J., LOMAN, N., LUBINSKI, J., MANOUKIAN, S., MITCHELL, G., MONTAGNA, M., NEUHAUSEN, S. L., NEVANLINNA, H., NIEDERACHER, D., NUSSBAUM, R. L., OFFIT, K., OLAH, E., OLOPADE, O. I., PARK, S. K., PIEDMONTE, M., RADICE, P., RAPPAPORT-FUERHAUSER, C., ROOKUS, M. A., SEYNAEVE, C., SIMARD, J., SINGER, C. F., SOUCY, P., SOUTHEY, M., STOPPA-LYONNET, D., SUKIENNICKI, G., SZABO,

C. I., TANCREDI, M., TEIXEIRA, M. R., TEO, S. H., TERRY, M. B., THOMASSEN, M., TIHOMIROVA, L., TISCHKOWITZ, M., TOLAND, A. E., TOLOCZKO-GRABAREK, A., TUNG, N., VAN RENSBURG, E. J., VILLANO, D., WANG-GOHRKE, S., WAPPENSCHMIDT, B., WEITZEL, J. N., ZIDAN, J., ZORN, K. K., MCGUFFOG, L., EASTON, D., et al. 2016. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 18, 112.

21. SAIDI, S. 2016. Consider the twist. Australian Doctor.

22. TEJADA-BERGES, T. 2016. Breast cancer: Genetics and risk assessment. Clinical Obstetrics and Gynecology, 59, 673-687.

23. WAN, K. M., CARTER, J. & PHILP, S. 2016. Predictors of early discharge after open gynecological surgery in the setting of an enhanced recovery after surgery protocol. Journal of Obstetrics and Gynaecology Research, 42, 1369-1374.

Head and Neck Cancer Publications1. ABDUL-RAZAK, M., CHUNG, H., WONG, E., PALME, C., VENESS, M., FARLOW, D., COLEMAN, H. & MORGAN, G. 2016. Sentinel lymph node biopsy for early oral cancers: Westmead Hospital experience. Australian and New Zealand Journal of Surgery, 87, 65-69.

2. BUCHANAN, M. A., COLEMAN, H. G., DALEY, J., DIGGES, J., SANDLER, M., RIFFAT, F. & PALME, C. E. 2016a. Relationship between CO2 laser-induced artifact and glottic cancer surgical margins at variable power doses. Head Neck, 38 Suppl 1, E712-6.

3. BUCHANAN, M. A., RIFFAT, F. & PALME, C. E. 2016b. Endoscopic vocal fold injection using a 25-gauge butterfly needle. Journal of Laryngology and Otolaryngology, 130, 398-400.

4. BUCKLEY, L., GUPTA, R., ASHFORD, B., JABBOUR, J. & CLARK, J. R. 2016. Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms.


Australian and New Zealand Journal of Surgery, 86, 442-7.

5. BURGESS, M., LEUNG, M., CHELLAPAH, A., CLARK, J. R. & BATSTONE, M. D. 2016. Osseointegrated implants into a variety of composite free flaps: A comparative analysis. Head Neck, 39, 443-447.

6. CH’NG, S., SKORACKI, R. J., SELBER, J. C., YU, P., MARTIN, J. W., HOFSTEDE, T. M., CHAMBERS, M. S., LIU, J. & HANASONO, M. M. 2016. Osseointegrated implant-based dental rehabilitation in head and neck reconstruction patients. Head Neck, 38 Suppl 1, E321-7.

7. CHIA, N., WEN, L., LYONS, J. G., ELLIOT, M., BADLANI, J., GAO, K., WAN, Z., LEE, M., CLIFFORD, A., SHANNON, K., PALME, C. E., CLARK, J. R. & GUPTA, R. 2016. The challenges and recommendations for minimally resourced biobanks in tertiary Australian hospitals. Australian and New Zealand Journal of Surgery, in press.

8. CHONG, L., EVISTON, T. & CLARK, J. R. 2016a. Innervated segmented vastus lateralis for mid-facial reanimation during radical parotidectomy. Head Neck, in press.

9. CHONG, L., EVISTON, T., LOW, H., HASMAT, S., COULSON, S. & CLARK, J. R. 2016b. Validation of the clinician-graded electronic facial paralysis assessment: The eFACE. Plastic and Reconstructive Surgery, in press.

10. CRAIG, S., ZHANG, A., CLARK, J. R. & ASHFORD, B. 2016. Laparascopic harvest of the gastro-omental free flap for reconstruction following total pharyngolaryngectomy: Operative technique. Head Neck, in press.

11. DELIC, N. C., LYONS, J. G., DI GIROLAMO, N. & HALLIDAY, G. M. 2016. Damaging effects of ultraviolet radiation on the cornea. Photochemistry and Photobiology.

12. EBRAHIMI, A., GIL, Z., AMIT, M., YEN, T. C., LIAO, C. T., CHATTURVEDI, P., AGARWAL, J., KOWALSKI, L., KREPPEL, M., CERNEA, C., BRANDAO, J., BACHAR, G., VILLARET, A. B., FLISS, D., FRIDMAN, E., ROBBINS,

K. T., SHAH, J., PATEL, S., CLARK, J., INTERNATIONAL CONSORTIUM FOR OUTCOME RESEARCH IN, H. & NECK, C. 2016. Comparison of the American Joint Committee on Cancer N1 versus N2a nodal categories for predicting survival and recurrence in patients with oral cancer: Time to acknowledge an arbitrary distinction and modify the system. Head Neck, 38, 135-9.

13. EVISTON, T. J. & KRISHNAN, A. V. 2016. Assessment of axonal excitability properties in two branches of the human facial nerve. Journal of Neuroscience Methods, 274, 53-60.

14. EVISTON, T. J., YABE, T. E., GUPTA, R., EBRAHIMI, A. & CLARK, J. R. 2016. Parotidectomy: surgery in evolution. Australian and New Zealand Journal of Surgery, 86, 193-9.

15. GORE, S. M., SHAW, D., MARTIN, R. C., KELDER, W., ROTH, K., UREN, R., GAO, K., DAVIES, S., ASHFORD, B. G., NGO, Q., SHANNON, K. & CLARK, J. R. 2016. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck, 38 Suppl 1, E884-9.

16. HABIB, M., MURGASEN, J., GAO, K., ASHFORD, B., SHANNON, K., EBRAHIMI, A. & CLARK, J. R. 2016. Contralateral neck failure in lateralized oral squamous cell carcinoma. Australian and New Zealand Journal of Surgery, 86, 188-92.

17. HASAN, Z., DWIVEDI, R. C., GUNARATNE, D. A., VIRK, S. A., PALME, C. E. & RIFFAT, F. 2016. Systematic review and meta-analysis of the complications of salvage total laryngectomy. European Journal of Surgical Oncology, 43, 42-51.

18. HASMAT, S., LOVELL, N. H., SUANING, G. J., LOW, T. H. & CLARK, J. 2016. Restoration of eye closure in facial paralysis using implantable electromagnetic actuator. Journal of Plastic Reconstructive and Aesthetic Surgery, 69, 1521-1525.

19. HEIDUSCHKA, G., VIRK, S. A., PALME, C. E., CH’NG, S., ELLIOT, M., GUPTA, R. & CLARK, J. 2016. Margin to tumor thickness ratio - A predictor

of local recurrence and survival in oral squamous cell carcinoma. Oral Oncology, 55, 49-54.

20. HONG, A., LEE, C. S., JONES, D., VEILLARD, A. S., ZHANG, M., ZHANG, X., SMEE, R., CORRY, J., PORCEDDU, S., MILROSS, C., ELLIOTT, M., CLARK, J. & ROSE, B. 2016a. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head & Neck, 38, 743-50. *

21. HONG, A., ZHANG, X., JONES, D., VEILLARD, A. S., ZHANG, M., MARTIN, A., LYONS, J. G., LEE, C. S. & ROSE, B. 2016b. Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 118, 342-9. *

22. HONG, A., ZHANG, X., JONES, D., ZHANG, M., LEE, C. S., LYONS, J. G., VEILLARD, A. S. & ROSE, B. 2016c. E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer. Cancer Biology and Therapy, 17, 181-7. *

2. JABBOUR, J., EBRAHIMI, A., SHEPHERD, H., MILROSS, C., SUNDARESAN, P., DHILLON, H. & CLARK, J. R. 2016a. Head and neck cancer patient education and support needs--A multi-institution survey. Cancer, in press. *

24. JABBOUR, J., LIU, W., LIMMER, A. & CLARK, J. R. 2016b. Trans-oral robotic surgery in oropharyngeal carcinoma: A guide for general practitioners. Australian Family Physician, in press.

25. JABBOUR, J., SHEPHERD, H., MILROSS, C., SUNDARESAN, P., CLARK, J. R. & DHILLON, H. 2016c. Challenges in producing tailored internet patient education materials. International Journal of Radiation Oncology, Biology, Physics, in press. *

26. JOHNSON, S., CLAYTON, J., BUTOW, P. N., SILVESTER, W., DETERING, K., HALL, J., KIELY, B. E., CEBON, J., CLARKE, S., BELL, M. L., STOCKLER, M., BEALE, P. & TATTERSALL, M. H. 2016. Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial. BMJ Open, 6, e012387.*


27. KIRKPATRICK, D., LUK, P. P., SELINGER, C. I., JOSEPH, D., MORGAN, G., GUPTA, R. & MCKENZIE, C. 2016. Metastatic adenoid cystic carcinoma of the liver confirmed with MYB rearrangement. Pathology, 48, s134.

28. LEE, M., BUCHANAN, M. A., RIFFAT, F. & PALME, C. E. 2016. Complications after CO2 laser surgery for early glottic cancer: An institutional experience. Head Neck, 38 Suppl 1, E987-90.

29. LI, M. K., NILES, N., GORE, S., EBRAHIMI, A., MCGUINNESS, J. & CLARK, J. R. 2016. Social perception of morbidity in facial nerve paralysis. Head Neck, 38, 1158-63.

30. LOBO, E. P., DELIC, N. C., RICHARDSON, A., RAVIRAJ, V., HALLIDAY, G. M., DI GIROLAMO, N., MYERSCOUGH, M. R. & LYONS, J. G. 2016. Self-organized centripetal movement of corneal epithelium in the absence of external cues. Nature Communications, 7, 12388.

31. LORD, M. S., CHENG, B., TANG, F., LYONS, J. G., RNJAK-KOVACINA, J. & WHITELOCK, J. M. 2016. Bioengineered human heparin with anticoagulant activity. Metabolic Engineering, 38, 105-114.

32. LOW, H., GAO, K., ELLIOT, M., CLIFFORD, A., SHANNON, K., GUPTA, R. & CLARK, J. R. 2016a. Factors predicting poor outcomes in T1 oral squamous cell carcinoma--Indicators for treatment intensification. Australian and New Zealand Journal of Surgery, 86, 366-371.

33. LOW, T. H., GAO, K., GUPTA, R., CLIFFORD, A., ELLIOTT, M., CH’NG, S., MILROSS, C. & CLARK, J. R. 2016b. Factors predicting poor outcomes in T1N0 oral squamous cell carcinoma: indicators for treatment intensification. Australian and New Zealand Journal of Surgery, 86, 366-71. *

34. LUK, P. P., SELINGER, C. I., EVISTON, T., EKMEJIAN, R., FOO, D., TAY, J., GAO, K., CH’NG, S., O’TOOLE, S. A., CLARK, J. R. & GUPTA, R. 2016a. Diagnostic and prognostic utility of MYB gene rearrangement detected by fluorescent in situ hybridization (FISH) in adenoid cystic carcinoma. Pathology, 48, s140.

35. LUK, P. P., WESTON, J. D., YU, B., SELINGER, C. I., EKMEJIAN, R., EVISTON, T. J., LUM, T., GAO, K., BOYER, M., O’TOOLE, S. A., CLARK, J. R. & GUPTA, R. 2016b. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck, 38 Suppl 1, E1838-47. *

36. LUK, P. P., WYKES, J., SELINGER, C. I., EKMEJIAN, R., TAY, J., GAO, K., EVISTON, T. J., LUM, T., O’TOOLE, S. A., CLARK, J. R. & GUPTA, R. 2016c. Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 121, 530-41.

37. MA, C. S., WONG, N., RAO, G., NGUYEN, A., AVERY, D. T., PAYNE, K., TORPY, J., O’YOUNG, P., DEENICK, E., BUSTAMANTE, J., PUEL, A., OKADA, S., KOBAYASHI, M., MARTINEZ-BARRICARTE, R., ELLIOTT, M., SEBNEM KILIC, S., EL BAGHDADI, J., MINEGISHI, Y., BOUSFIHA, A., ROBERTSON, N., HAMBLETON, S., ARKWRIGHT, P. D., FRENCH, M., BLINCOE, A. K., HSU, P., CAMPBELL, D. E., STORMON, M. O., WONG, M., ADELSTEIN, S., FULCHER, D. A., COOK, M. C., STEPENSKY, P., BOZTUG, K., BEIER, R., IKINCIOGULLARI, A., ZIEGLER, J. B., GRAY, P., PICARD, C., BOISSON-DUPUIS, S., PHAN, T. G., GRIMBACHER, B., WARNATZ, K., HOLLAND, S. M., UZEL, G., CASANOVA, J. L. & TANGYE, S. G. 2016. Unique and shared signaling pathways cooperate to regulate the differentiation of human CD4+ T cells into distinct effector subsets. Journal of Experimental Medicine, 213, 1589-608.

38. MAHER, N. G., COLLGROS, H., URIBE, P., CH’NG, S., RAJADHYAKSHA, M. & GUITERA, P. 2016. In vivo confocal microscopy for the oral cavity: Current state of the field and future potential. Oral Oncology, 54, 28-35.

39. MATTHEWS, T. J., CHUA, E., GARGYA, A., CLARK, J., GAO, K. & ELLIOTT, M. 2016. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study. Journal of Laryngology and Otololaryngology, 130 Suppl 4, S50-3.

40. MCANDREW, D., BUCKLEY, L., ASHFORD, B. & CLARK, J. R. 2016. Anatomical mapping of the omental vasculature to refine its optimal use in free flap transfer. FASEB Journal, 29, 544.3.

41. MELI, A. P., FONTES, G., AVERY, D. T., LEDDON, S. A., TAM, M., ELLIOT, M., BALLESTEROS-TATO, A., MILLER, J., STEVENSON, M. M., FOWELL, D. J., TANGYE, S. G. & KING, I. L. 2016. The integrin LFA-1 controls T follicular helper cell generation and maintenance. Immunity, 45, 831-846.

42. MOROSIN, T., ASHFORD, B., RANSON, M., GUPTA, R., CLARK, J., IYER, N. G. & SPRING, K. 2016. Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study. Oncotarget, 7, 47111-47115.

43. O’NEIL, L. M., PALME, C. E., RIFFAT, F. & MAHANT, N. 2016. Botulinum toxin for the management of Sjogren syndrome-associated recurrent parotitis. Journal of Oral and Maxillofacial Surgery, 74, 2428-2430.

44. ONG, W., ZHAO, R., LUI, B., TAN, W., EBRAHIMI, A., CLARK, J. R., SOO, K. C., TAN, N. C., TAN, H. K. & IYER, N. G. 2016. Prognostic significance of lymph node density in squamous cell carcinoma of the tongue. Head Neck, 38 Suppl 1, E859-66.

45. PARFITT, G. J., LEWIS, P. N., YOUNG, R. D., RICHARDSON, A., LYONS, J. G., DI GIROLAMO, N. & JESTER, J. V. 2016. Renewal of the holocrine Meibomian glands by label-retaining, unipotent epithelial progenitors. Stem Cell Reports, 7, 399-410.

46. PHAM, M., EVISTON, T. J. & CLARK, J. R. 2016. Reconstruction of limited parotidectomy defects using the dermofat graft. Australian and New Zealand Journal of Surgery.


47. SATGUNASEELAN, L., GUPTA, R., MADORE, J., CHIA, N., LUM, T., PALME, C. E., BOYER, M., SCOLYER, R. A. & CLARK, J. R. 2016a. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 48, 574-80. *

48. SATGUNASEELAN, L., VIRK, S., LUM, T., IYER, N. G., GUPTA, R. & CLARK, J. 2016b. A geographical comparison of p16 expression in squamous cell carcinoma (SCC) of the tounge. Pathology, 48, s154-s154.

49. SATGUNASEELAN, L., VIRK, S. A., LUM, T., GAO, K., CLARK, J. R. & GUPTA, R. 2016c. p16 expression independent of human papillomavirus is associated with lower stage and longer disease-free survival in oral cavity squamous cell carcinoma. Pathology, 48, 441-8.

50. SAW, R. P., MENZIES, A. M., GUMINSKI, A., NIEWEG, O. E., SHANNON, K., GONZALEZ, M., CH’NG, S., KEFFORD, R. F., THOMPSON, J. F., STRETCH, J., SPILLANE, A. J., SCOLYER, R. A. & LONG, G. V. 2016. Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIb/c BRAF-V600 mutation positive melanoma. Journal of Clinical Oncology, 43, 9583.

51. SMITH, J. A., VIRK, S., PALME, C. E., LOW, T. H., CH’NG, S., GUPTA, R., GAO, K. & CLARK, J. R. 2016. Age is not a predictor of prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. Australian and New Zealand Journal of Surgery.

52. VARGAS, A. C., SELINGER, C. I., SATGUNASEELAN, L., COOPER, W. A., GUPTA, R., STALLEY, P., BROWN, W., SOPER, J., SCHATZ, J., BOYLE, R., THOMAS, D. M., TATTERSALL, M. H., BHADRI, V. A., MACLEAN, F., BONAR, S. F., SCOLYER, R. A., KARIM, R. Z., MCCARTHY, S. W., MAHAR, A. & O’TOOLE, S. A. 2016. Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69, 1000-1011.*

53. WOON, H. G., BRAUN, A., LI, J., SMITH, C., EDWARDS, J., SIERRO, F., FENG, C. G., KHANNA, R., ELLIOT, M., BELL, A., HISLOP, A. D., TANGYE, S. G., RICKINSON, A. B., GEBHARDT, T., BRITTON, W. J. & PALENDIRA, U. 2016. Compartmentalization of total and virus-specific tissue-resident memory CD8+ T cells in human lymphoid organs. PLoS Pathology, 12, e1005799.

54. ZHANG, X., GEE, H., ROSE, B., LEE, C. S., CLARK, J., ELLIOTT, M., GAMBLE, J. R., CAIRNS, M. J., HARRIS, A., KHOURY, S. & TRAN, N. 2016. Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 16, 86.


department

Grants

1. Dinger M. AI: Clark J. Genetic Stratification of tumours of the head, neck, pituitary and skull base – identifying prognostic and new therapeutic targets. Cancer Council NSW. $360,000. (2015–2016)

Prof Carsten Palme, Director Head and Neck Unit

Chris O’Brien Lifehouse Research Report 2016 PB32

Above: Professor Chris O’Brien; front cover (main) researcher; (left-right): laboratory centrifuge; Research Forum poster viewing; Clinical Trials; researcher; Dr Toni Lindsay

Research Report 2016

C o m p a s s i o n i n n o V a T i o n

FOR MORE INFORMATIONChris O’Brien Lifehouse119-143 Missenden RoadCamperdown NSW 2050

Mailing AddressPO Box M5Missenden RoadCamperdown NSW 2050

Phone: 1300 852 500Fax: + 61 2 9383 1000Email: [email protected]: www.mylifehouse.org.au

Research Report 2016 - Chris O'Brien Lifehouse

Documents

Transcript of Research Report 2016 - Chris O'Brien Lifehouse